CURRICULUM VITAE FLORA E. VAN LEEUWEN 1. Personal details Name : Flora E. van Leeuwen Date of Birth : August 13, 1956 Work Address : Netherlands Cancer Institute Department of Epidemiology + Division of Psychosocial Research and Epidemiology Plesmanlaan 121 1066 CX Amsterdam The Netherlands Tel: 31-205122483 Mail: f.v.leeuwen@nki.nl 2. Training 1981 M.Sc. Human Nutrition, Agricultural University Wageningen (cum laude). 1983 M.S.P.H. Epidemiology, University of Alabama in Birmingham, Birmingham, Alabama, USA. 1994 Ph.D. Epidemiology, Vrije Universiteit Amsterdam (cum laude). Thesis title: Second malignancy as a sequel to cancer treatment: an assessment of risk. Promotores: Prof.dr. J.P. Vandenbroucke, Prof.dr. H.M. Pinedo. 3. Work experience 2010 – present Head of Division of Psychosocial Research and Epidemiology,

Netherlands Cancer Institute, Amsterdam 1998 – present Professor (Chair in Cancer Epidemiology, EMGO Institute, Faculty of Medicine,

University of Amsterdam. 1989 – 2010 Consulting epidemiologist to the Comprehensive Cancer Center Amsterdam. 1986 – 2010 Head of the Subsection on Epidemiology,

Netherlands Cancer Institute, Amsterdam. 1981 – 1986 Head of the Tumor Registry, Clinical Trial Unit and Epidemiology Unit,

Netherlands Cancer Institute, Amsterdam. 4. Honors and awards 1994 PhD Thesis Cum Laude 1995 Henny C. Dirven Award for breast cancer research from the State University of Leiden. 1997 Prof. dr. P. Muntendam Award for Cancer Research, Dutch Cancer Society. 2005 Outstanding Alumnus Award, Wageningen University. 2010 Queen Wilhelmina Research Award of the Dutch Cancer Society for the research program:

Assessment of late effects of treatment for Hodgkin’s lymphoma 2019 17th Rosalind E. Franklin Award for Women in Science from the U.S. National Cancer Institute

5. Scientific research In the 1980s Flora van Leeuwen initiated the Epidemiology group of the Netherlands Cancer Institute. The Epidemiology group has currently expanded to 40 employees, and is part of the Division of Psychosocial Research and Epidemiology (75 employees), since 2010 headed by Flora van Leeuwen. The Cancer Epidemiology group of Flora E. van Leeuwen focuses on two principal research lines: (1) the assessment of the long-term risks of second malignancy and cardiovascular disease following treatment of Hodgkin lymphoma, non-Hodgkinlymphoma, breast cancer, testicular cancer and childhood malignancy, and: (2) the assessment of the roles of hormone-related and genetic risk factors in the etiology of breast and ovarian cancer. Special interest is in late effects of ovarian stimulation for in Vitro Fertilization and cancer etiology in BRCA1/2 families. Epidemiologic methods are combined with molecular analyses a) to examine gene-environment and gene-treatment interactions, and b) to differentiate risk factors for cancer according to specific genetic

alterations in the tumor. There is extensive experience in the conduct of large-scale cohort studies and linkage with disease registries. Flora van Leeuwen established several large cohorts of cancer patients i.e. survivors of Hodgkin lymphoma (HL), testicular cancer and breast cancer. She also established the OMEGA cohort of subfertile women treated with hormone stimulation for IVF and the Hereditary Breast and Ovarian Cancer Consortium (HEBON), a nationwide cohort of individuals tested for BRCA mutations. She has been awarded a large number of grants on late adverse effects of cancer treatment; in addition she established and coordinates the Dutch BETER consortium, aimed at the establishment of survivorship clinics for survivors of lymphoma in 24 Dutch hospitals. 6. Board positions Current positions 1996 – present Member of Scientific Advisory Board of the Netherlands DES Center. 1997 – present Member of Steering Group of the Netherlands Collaborative Group on Heriditary

Breast en Ovarian Cancer (HEBON) 1997 – present Member of Netherlands Expert Group on DES-related Health effects 1998 – present Member of Steering Group of the Collaborative Group on Hormonal Factors in Breast

Cancer (coordinated by ICRF Cancer Epidemiology Unit, Oxford, United Kingdom 2001 – present Member of Advisory Board of Coalition for Lymphoma patients (Hematon) 2006 – present Member of CBS (Statistics Netherlands) Committee on provision of cause of death

information for research 2008 – present Member of Steering Group of LATER: Late Effects Registration in Childhood

Cancer Survivors 2010 - present Member of the Board of the Dutch Association for Oncology 2011 – present Member of the US Childhood Cancer Survivor Study (CCSS) External Advisory

Committee 2012 - present Member of Scientific Committee of the European Code Against Cancer project,

International Agency for Research in Cancer 2016 - present Member of the Dutch Task Force on Cancer Survivorship Issues 2017 - present Vice-Chairman of Sounding Board of Chromium-6 exposure in Dutch occupational

settings 2017 - present Fellow of the European Academy of Cancer Sciences Past (since 1996, selection) 1998 – 2008 Chairman of the Netherlands Working Party “Cancer Epidemiology” of the Dutch

Cancer Society 1999 - 2015 Member of Permanent Health Council Committee on Health effects of

Electromagnetic Fields and Radiofrequency radiation 2001 – 2012 Member of the Dutch Health Council 2002 – 2006 Member of the Scientific Council of the International Agency for Research on

Cancer. 2002 – 2006 Member of the Academy Council for Medical Sciences of the Royal Netherlands

Academy of Arts and Sciences2002 – 2015 Member of Consideration Group of the Health Council “Health rights and Ethics”. 2003 – 2012 Chairman of Scientific Advisory Committee of Dutch study on “Cancer risk in the

Balkan military”, coordinated by RIVM.2003 – 2016 Scientific review board of Pink Ribbon, The Netherlands 2005 – 2013 Member of Advisory Board of Coalition for Breast Cancer Patients. 2006 – 2015 Scientific Review Board of the Dutch Cancer Society and two subcomittees 2007 – 2010 Member of Health Council Committee on Radiotherapy 2009 – 2015 Member of Steering group of Biobanking and Biomolecular Resources Research

infrastructure (BBMRI)2010 – 2015 Chairman of Committee Cardio-oncology of the Dutch Cancer Society and the

Netherlands Heart Foundation 2011 – 2016 Member of Presidium of the Scientific Review Board of the Dutch Cancer Society2013 – 2016 Member of the Cancer Survivorship Committee of the American Society of Clinical

Oncology 2014 – 2016 Chairman of the Prevention Committee of the Dutch Cancer Society

FLORA E. VAN LEEUWEN: PUBLICATIONS

THESIS

Van Leeuwen FE. Second malignancy as a sequel to cancer treatment: an assessment of risk [dissertation] VU University Amsterdam, 1994. Hirsch Index 77

INTERNATIONAL JOURNALS BY SUBJECT

TOPICS OF THIS PUBLICATION LIST ARE: I. Late adverse effects of cancer treatment II. Etiology of breast cancer and other hormone-related cancers III. Ovarian stimulation for IVF IV. General cancer epidemiology and mixed topics V. Methods, privacy legislation and ethical issues

I. Late adverse effects of cancer treatment Kok JL, Teepen JC, van der Pal HJ, van Leeuwen FE, Tissing WJE, Neggers S, Loonen JJ, Louwerens M, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Jaspers MMW, van Santen HM, van der Heiden-van der Loo M, Janssens GO, Maduro JH, Bruggink AH, Jongmans MC, Kremer LCM, Ronckers CM. Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer. JAMA Oncol. 2019. Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ, Seynaeve CM, Baaijens MHA, Gietema JA, Darby SC, van Leeuwen FE, Aleman BMP, Taylor CW. Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. International journal of radiation oncology, biology, physics. 2019;103(3):595-604. Becherer BE, de Boer M, Spronk PER, Gijsbers AH, de Boer JP, van Leeuwen FE, Mureau MAM, van der Hulst RJW, de Jong D, Rakhorst HA. The Dutch Breast Implant Registry (DBIR): Registration of Breast Implant - Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), a proof of concept. Plastic and Reconstructive Surgery 2019;In press. Feijen E, Font-Gonzalez A, Van der Pal HJH, Kok WEM, Geskus RB, Ronckers CM, Bresters D, van Dalen EC, van Dulmen-den Broeder E, van den Berg MH, van der Heiden-van der Loo M, van den Heuvel-Eibrink MM, van Leeuwen FE, Loonen JJ, Neggers S, Versluys ABB, Tissing WJE, Kremer LCM. Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study. Journal of the American Heart Association. 2019;8(1):e009122. Kok JL, Teepen JC, van Leeuwen FE, Tissing WJE, Neggers SJCMM, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, van der Heiden-van der Loo M, Aleman BMP, Daniels L, Haasbeek CJA, Hoeben B, Janssens G, Maduro J, Oldenburger F, van Rij C, Tersteeg RJHA, Hauptman M, Kremer LCM, Ronckers CM, Group tD-LS. Meningioma risk after childhood cancer in the DCOG-LATER cohort: roles of radiation dose and volume. Neuro-Oncology. 2018;In Press. Rigter LS, Schaapveld M, Janus CPM, Krol ADG, van der Maazen RWM, Roesink J, Zijlstra JM, van Imhoff GW, Poortmans PMP, Beijert M, Lugtenburg PJ, Visser O, Snaebjornsson P, van Eggermond AM, Aleman BMP, van Leeuwen FE, van Leerdam ME. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer. Cancer medicine. 2018. Rigter LS, Snaebjornsson P, Rosenberg EH, Atmodimedjo PN, Aleman BM, Ten Hoeve J, Geurts-Giele WR, van Ravesteyn TW, Hoeksel J, Meijer GA, Te Riele H, van Leeuwen FE, Dinjens WN, van Leerdam ME. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer

after Hodgkin's lymphoma treatment. Gut. 2018;67(3):447-455. de Jong D, de Boer M, van Leeuwen FE. Risk of Breast Implant-Associated Anaplastic Large Cell Lymphoma-Reply. JAMA oncology. 2018;4(10):1435. van den Berg MH, Overbeek A, Lambalk CB, Kaspers GJL, Bresters D, van den Heuvel-Eibrink MM, Kremer LC, Loonen JJ, van der Pal HJ, Ronckers CM, Tissing WJE, Versluys AB, van der Heiden-van der Loo M, Heijboer AC, Hauptmann M, Twisk JWR, Laven JSE, Beerendonk CCM, van Leeuwen FE, van Dulmen-den Broeder E. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Hum Reprod. 2018. Opstal-van Winden AWJ, de Haan HG, Hauptmann M, Schmidt MK, Broeks A, Russell NS, Janus CPM, Krol ADG, van der Baan FH, De Bruin ML, van Eggermond AM, Dennis J, Anton Culver H, Haiman CA, Sawyer EJ, Cox A, Devilee P, Hooning MJ, Peto J, Couch FJ, Pharoah P, Orr N, Easton DF, Aleman BMP, Strong LC, Bhatia S, Cooke R, Robison LL, Swerdlow AJ, van Leeuwen FE. Genetic susceptibility to radiation-induced breast cancer after Hodgkin Lymphoma. Blood. 2018. Krul IM, Opstal-van Winden AWJ, Janus CPM, Daniels LA, Appelman Y, Maas A, de Vries S, Jozwiak K, Aleman BMP, van Leeuwen FE. Cardiovascular Disease Risk After Treatment-Induced Premature Ovarian Insufficiency in Female Survivors of Hodgkin Lymphoma. J Am Coll Cardiol. 2018;72(25):3374-3375. Rigter LS, Spaander MCW, Aleman BMP, Bisseling TM, Moons LM, Cats A, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, van der Maazen RWM, Snaebjornsson P, Kuipers EJ, Bruno MJ, Dekker E, Meijer GA, de Boer JP, van Leeuwen FE, van Leerdam ME. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors. Cancer. 2018. de Vries S, Schaapveld M, Kardaun JW, de Bruin KH, Krol AD, Lugtenburg PJ, Jacobse JN, Aleman BM, van Leeuwen FE. Comparing causes of death of Hodgkin lymphoma and breast cancer patients between medical records and cause-of-death statistics. Clinical epidemiology. 2018;10:1523-1531 Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, Bierman C, van Leeuwen FE, Rutgers EJ, Schmidt MK, Lips EH, Wesseling J. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;24(15):3593-3601. Elshof LE, Schmidt MK, Rutgers EJT, van Leeuwen FE, Wesseling J, Schaapveld M. Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Annals of surgery. 2018;267(5):952-958. Starreveld DEJ, Daniels LA, Valdimarsdottir HB, Redd WH, de Geus JL, Ancoli-Israel S, Lutgendorf S, Korse CM, Kieffer JM, van Leeuwen FE, Bleiker EMA. Light therapy as a treatment of cancer-related fatigue in (non-)Hodgkin lymphoma survivors (SPARKLE trial): study protocol of a multicenter randomized controlled trial. BMC Cancer. 2018;18(1):880. van den Berg M, van Dijk M, Byrne J, Campbell H, Berger C, Borgmann-Staudt A, Calaminus G, Dirksen U, Winther JF, Fossa SD, Grabow D, Grandage VL, van den Heuvel-Eibrink MM, Kaiser M, Kepak T, Kremer LC, Kruseova J, Kuehni CE, Lambalk CB, van Leeuwen FE, Leiper A, Modan-Moses D, Morsellino V, Spix C, Kaatsch P, van Dulmen-den Broeder E. Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). JMIR research protocols. 2018;7(9):e10824. H.J.Groot, J.A. Gietema, B.M.P.Aleman, L.Incrocci , R.de Wit, A.J. Witjes, G. Groenewegen, P. de Brouwer, O.W.M. Meijer, M.C.C.M. Hulshof, H.A. van den Berg, T. J. Smilde, B. G.L. Vanneste, M. J. Aarts, A.C.M. van den Bergh, A.W. van den Belt-Dusebout, S.Lubberts, K.Jóźwiak, S. Horenblas, F.E. van Leeuwen, Schaapveld M. Risk of Diabetes Mellitus after para-aortic radiation for testicular cancer Br J Cancer. 2018;In press. Byrne J, Grabow D, Campbell H, O'Brien K, Bielack S, Am Zehnhoff-Dinnesen A, Calaminus G, Kremer L, Langer T, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Baust K, Bautz A, Beck JD, Berger C, Binder H, Borgmann-Staudt A, Broer L, Cario H, Casagranda L, Clemens E, Deuster D, de Vries A, Dirksen U, Falck Winther J, Fossa S, Font-Gonzalez A, Grandage V, Haupt R, Hecker-Nolting S, Hjorth L, Kaiser M, Kenborg L, Kepak T, Kepakova K, Knudsen LE, Krawczuk-Rybak M, Kruseova J, Kuehni CE, Kunstreich M, Kuonen R, Lackner H, Leiper A, Loeffen EAH, Luks A, Modan-

Moses D, Mulder R, Parfitt R, Paul NW, Ranft A, Ruud E, Schilling R, Spix C, Stefanowicz J, Straubeta G, Uitterlinden AG, van den Berg M, van der Kooi AL, van Dijk M, van Leeuwen F, Zolk O, Zoller D, Kaatsch P. PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. Eur J Cancer. 2018;103:227-237. Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet Haematology. 2018;doi: 10.1016/S2352-3026(18)30051-6. [Epub ahead of print]. Teepen JC, Curtis RE, Dores GM, Berrington de Gonzalez A, van den Heuvel-Eibrink MM, Kremer LCM, Gilbert ES, van Leeuwen FE, Ronckers CM, Morton LM. Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014. Leukemia. 2018;doi: 10.1038/s41375-018-0149-2. [Epub ahead of print]. Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klumpen HJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Incrocci L, van den Bergh ACM, Jozwiak K, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. J Clin Oncol. 2018:Jco2017774174. Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gietema JA, Duane FK, Taylor CW, Darby SC, Hauptmann M, Seynaeve CM, Baaijens MHA, Sonke GS, Rutgers EJT, Russell NS, Aleman BMP, van Leeuwen FE. Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. Br J Cancer. 2018 Meulepas JM, Ronckers CM, Smets A, Nievelstein RAJ, Gradowska P, Lee C, Jahnen A, van Straten M, de Wit MY, Zonnenberg B, Klein WM, Merks JH, Visser O, van Leeuwen FE, Hauptmann M. Radiation Exposure From Pediatric CT Scans and Subsequent Cancer Risk in the Netherlands. J Natl Cancer Inst. 2018;doi: 10.1093/jnci/djy104. [Epub ahead of print]. Teepen JC, Kok JL, van Leeuwen FE, Tissing WJE, Dolsma WV, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, van den Berg MH, van der Heiden-van der Loo M, Hauptmann M, Jongmans MC, Overbeek LI, van de Vijver MJ, Kremer LCM, Ronckers CM, Aleman BMP, van den Berg MH, Bresters D, Caron HN, Daniels LA, Dolsma W, van Dulmen-den Broeder E, Grootenhuis MA, Haasbeek CJ, den Hartogh JG, Hauptmann M, van der Heiden-van der Loo M, van den Heuvel-Eibrink MM, Hollema N, Janssens GO, Jongmans MC, Jaspers MWM, Kok JL, Kremer LCM, van Leeuwen FE, Loonen J, Maduro JH, Neggers SJCMM, Oldenburger F, Overbeek LI, van der Pal HJ, Postma A, de Ridder-Sluiter JG, van Rij CM, Ronckers CM, Teepen JC, Tersteeg RJ, Tissing WJE, Versluys AB, van de Vijver MJ, Zsíros J. Colorectal Adenomas and Cancers After Childhood Cancer Treatment: A DCOG-LATER Record Linkage Study. JNCI: Journal of the National Cancer Institute. 2018:djx266. de Vries S, Schaapveld M, Van Nimwegen FA, Jóźwiak K, Lugtenburg PJ, Daniels L, Roesink J, Van der Maazen R, Kok WE, Aleman B, Van Leeuwen FE. High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors. British journal of cancer. 2017; In press. Turcotte LM, Neglia JP, Reulen RC, Ronckers CM, van Leeuwen FE, Morton LM, Hodgson DC, Yasui Y, Oeffinger KC, Henderson TO. Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(21):2145-2152. Krul IM, Opstal-van Winden AWJ, Zijlstra JM, Appelman Y, Schagen SB, Meijboom LJ, Serné E, Lambalk CB, Lips P, van Dulmen-den Broeder E, Hauptmann M, Daniëls LA, Aleman BMP, Van Leeuwen FE. Rationale and design of a cohort Study On Primary ovarian insufficiency in female survivors of Hodgkin lymphoma: Influence on long-term Adverse effects (SOPHIA). BMJ Open. 2017; in press.

Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits M, Nederlof PM, van Boven HH, Linn SC, van Leeuwen FE, Wessels LFA, Zwart W. Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors. PNAS. 2017;DOI 10.1073/pnas.1615233114. Krul IM, Opstal-van Winden AWJ, Aleman BMP, Janus CPM, van Eggermond AM, De Bruin ML, Hauptmann M, Krol ADG, Schaapveld M, Broeks A, Kooijman KR, Fase S, Lybeert ML, Zijlstra JM, van der Maazen RWM, Kesminiene A, Diallo I, de Vathaire F, Russell NS, van Leeuwen FE. Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure. International journal of radiation oncology, biology, physics. 2017;99(4):843. van Leeuwen FE, Ng AK. Late sequelae in Hodgkin lymphoma survivors. Hematol Oncol. 2017;35 Suppl 1:60. Chow EJ, Chen Y, Hudson MM, Feijen EAM, Kremer LC, Border WL, Green DM, Meacham LR, Mulrooney DA, Ness KK, Oeffinger KC, Ronckers CM, Sklar CA, Stovall M, van der Pal HJ, van Dijk I, van Leeuwen FE, Weathers RE, Robison LL, Armstrong GT, Yasui Y. Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer. J Clin Oncol. 2017:Jco2017748673. Russell NS, Krul IM, van Eggermond AM, Aleman BMP, Cooke R, Kuiper S, Allen SD, Wallis MG, Llanas D, Diallo I, de Vathaire F, Smith SA, Hauptmann M, Broeks A, Swerdlow AJ, Van Leeuwen FE. Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy. Clinical and Translational Radiation Oncology. 2017;7(Supplement C):20. Moskowitz CS, Chou JF, Sklar CA, Barnea D, Ronckers CM, Friedman DN, Neglia JP, Turcotte L, Howell RM, Henderson TO, Armstrong GT, Leisenring WM, Robison LL, van Leeuwen FE, Pike MC, Oeffinger KC. Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study. Br J Cancer. 2017;117(2):290 van Eggermond AM, Schaapveld M, Janus CP, de Boer JP, Krol AD, Zijlstra JM, van der Maazen RW, Kremer LC, van Leerdam ME, Louwman MW, Visser O, De Bruin ML, Aleman BM, van Leeuwen FE. Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. Br J Cancer. 2017;117(3):306. Teepen JC, de Vroom SL, van Leeuwen FE, Tissing WJ, Kremer LC, Ronckers CM. A systematic review: Childhood cancer survivors and gastrointestinal cancer. Cancer treatment reviews. 2017;55:210. Teepen JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, van den Heuvel-Eibrink MM, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Neggers S, Jaspers MWM, Hauptmann M, van der Heiden-van der Loo M, Visser O, Kremer LCM, Ronckers CM. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. J Clin Oncol. 2017;35(20):2288. Font-Gonzalez A, Feijen EL, Geskus RB, Dijkgraaf MG, van der Pal HJ, Heinen RC, Jaspers MW, van Leeuwen FE, Reitsma JB, Caron HN, Sieswerda E, Kremer LC. Risk and associated risk factors of hospitalization for specific health problems over time in childhood cancer survivors: a medical record linkage study. Cancer medicine. 2017. van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, Janus CPM, Daniels L, van Leeuwen FE, Cutter DJ, Aleman BMP. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257. Hoedjes M, van Stralen MM, Joe STA, Rookus M, van Leeuwen FE, Michie S, Seidell JC, Kampman E. Toward the optimal strategy for sustained weight loss in overweight cancer survivors: a systematic review of the literature. J Cancer Surviv. 2017;11(3):360 Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, Schinagl DA, Rietveld DH, Versteegh MI, Visser O, Rutgers EJ, Aleman BM, van Leeuwen FE. Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors. Int J Radiat Oncol Biol Phys. 2016;94(5):1061. Jacobsen PB, Rowland JH, Paskett ED, Van Leeuwen FE, Moskowitz C, Katta S, Wollins D, Robison LL. Identification of Key Gaps in Cancer Survivorship Research: Findings From the American Society

of Clinical Oncology Survey. J Oncol Pract. 2016;12(3):190. Rigter LS, Snaebjornsson P, Rosenberg EH, Atmodimedjo PN, Aleman BM, ten Hoeve J, Geurts-Giele WR, van Ravesteyn TW, Hoeksel J, Meijer GA, te Riele H, van Leeuwen FE, Dinjens WN, van Leerdam ME. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. Gut. 2016;10.1136/gutjnl-2016-312608. van Dijk IW, van der Pal HJ, van Os RM, Roos YB, Sieswerda E, van Dalen EC, Ronckers CM, Oldenburger F, van Leeuwen FE, Caron HN, Koning CC, Kremer LC. Risk of Symptomatic Stroke After Radiation Therapy for Childhood Cancer: A Long-Term Follow-Up Cohort Analysis. Int J Radiat Oncol Biol Phys. 2016;96(3):597. Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits M, Nederlof PM, van Boven HH, Linn SC, van Leeuwen FE, Wessels LFA, Zwart W. Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors. PNAS. 2017;114980:E1316 Gilbert ES, Curtis RE, Hauptmann M, Kleinerman RA, Lynch CF, Stovall M, Smith SA, Weathers RE, Anderson M, Dores GM, Faumeni JFJ, Fossa SD, Hall P, Hodgson DC, Holowaty E, Joensuu H, Johannesen TB, Langmark F, Kaijser M, Pukkala E, Rajamaran P, Storm HH, Vaalavirta L, Van den Belt-Dusebout AW, Aleman BM, Travis LB, Morton LM, Van Leeuwen FE. Stomach cancer following Hodgkin lymphoma, testicular cancer, and cervical cancer: A pooled analysis of three international studies with a focus on radiation effects. Radiat Res 2017:187(2):186. Overbeek A, van den Berg MH, van Leeuwen FE, Kaspers GJL, Lambalk CB, van Dulmen-den Broeder E. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. Cancer Treat Rev. 2017;53:10. Rigter LS, Spaander MCW, Moons LM, Bisseling TM, Aleman BMP, de Boer JP, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, Raemaekers JMM, van der Maazen RWM, Cats A, Bleiker EMA, Snaebjornsson P, Carvalho B, Lansdorp-Vogelaar I, Jóźwiak K, te Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. BMC Cancer. 2017;17(1):112 Hauptmann M, Borge Johannesen T, Gilbert ES, Stovall M, van Leeuwen FE, Rajaraman P, Smith SA, Weathers RE, Aleman BMP, Andersson M, Curtis RE, Dores GM, Fraumeni Jr JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Morton LM, Fossa SD, Travis LB. Increased pancreatic cancer risk following radiotherapy for testicular cancer. Br J Cancer. 2016: 115; 901-908 Ng AK, van Leeuwen FE. Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance. Sem Hematol. 2016;53(3):209 Paalman C, van Leeuwen F, Aaronson N, de Boer A, van de Poll-Franse L, Oldenburg H, Schaapveld M. Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study. Br J Cancer. 2016;114(1):81. Rigter LS, Kallenberg FGJ, Bastiaansen B, van Os TAM, van Leeuwen FE, van Leerdam ME, Dekker E. A case series of intestinal adenomatous polyposis of unidentified etiology; a late effect of irradiation? BMC Cancer. 2016;16:862. Sieswerda E, Font-Gonzalez A, Reitsma JB, Dijkgraaf MG, Heinen RC, Jaspers MW, van der Pal HJ, van Leeuwen FE, Caron HN, Geskus RB. High hospitalization rates in survivors of childhood cancer: A longitudinal follow-up study using medical record linkage. PloS one. 2016;11(7):e0159518 Van Leeuwen FE, Ronckers CM. Anthracyclines and Alkylating Agents: New Risk Factors for Breast Cancer in Childhood Cancer Survivors? J Clin Oncol. 2016;34(9):891 Van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program. 2016;1:323. van Nimwegen FA, Cutter DJ, Schaapveld M, Darby SC, Aleman BM, van Leeuwen FE. Reply to D. Vordermark and T. Pelz and R. Mazzola et al. J Clin Oncol. 2016;34(24):2941. van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BMP, van Leeuwen FE. Radiation dose-response

relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235-43. Aleman BMP, Van Leeuwen FE. [No evidence for higher risk on coronary damage] Article in Dutch. Ned Tijdschr Geneeskd 2015;159:A8856 Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol ADG, Janus CPM, Van Leeuwen FE, Aleman BMP. Risk of valvular heart disease after tretment for Hodgkin Lymphoma. J Natl Cancer Inst 2015; 107(4): djv008. Schaapveld M, Aleman BMP, Van Eggermond AM, Janus CPM, Krol ADG, Van der Maazen RWM, Roesink j, Raemaekers JMM, De Boer JP, Zijlstra JM, Van Imhoff GW, Petersen EJ, Poortmans PMP, Beijert M, Lybert ML, Mulder I, Visser O, Louwman MWJ, Krul IM, Lugtenburg P, Van Leeuwen FE. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. NEJM. 2015; 373(26):2499. Van Nimwegen, F.A., Cutter, D.J., Schaapveld, M. Rutten, A., Kooijman, K., Krols, A.D.G., Janus C.P.M., Darby, S.C. Van Leeuwen F.E., Aleman, B.M.P. A simple method to estimate mean heart dose from Hodgkin lymphoma radiotherapy based on simulation X-rays. Int J Rad Onc Biol Phys 2015; 29(1): 153-160 van Nimwegen FA, Schaapveld M, Janus CM, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE. Cardiovascular disease after hodgkin lymphoma treatment: 40-year disease risk. JAMA Int Med 2015;175(6):1007-17 Van der Pal H, van Dijk IW, Geskus RB, Kok WB, Koolen M, Sieswerda E, Oldenburger F, Koning CC, Van Leeuwen FE, Caron HN, Kremer LC, Van Dalen EC. Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: A long-term follow-up study. Int J Radiat Oncol Biol Phys 2015;91(1):213-22 Boekel NB, Schaapveld M, Gietema JA, Rutgers EJT, Versteegh MIM, Visser O, Aleman BMP, van Leeuwen FE. Cardiovascular morbidity and mortality in a Dutch population-based cohort of patients treated for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2014;106(8). De Glas NA, Fontein DBY, Bastiaannet E, Pijpe A, Craen AJM, Liefers GJ, Nortier, HJWR, De Haes, HJCJM, van de Velde, CJJ, van Leeuwen, FE. Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study. Cancer 2014; 120(18):2847-54. Dores GM, Curtis RE, van Leeuwen FE, Stovall M, Hall P, Lynch CF, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Joensuu H, Johannesen TB, Andersson M, Holowaty EJ, Kaijser M, Pukkala E, Vaalavirta L, Fossa SD, Langmark F, Travis LB, Fraumeni JF Jr, Aleman BM, Morton LM, Gilbert ES Pancreatic cancer risk after treatment for Hodgkin lymphoma. Ann Oncol 2014; 25: 2073-2079. Hauptmann M, Fossa SD, Stovall M, van Leeuwen FE, Johannesen TB, Rajaraman P, Gilbert ES, Smith SA, Weathers RE, Aleman BMP, Andersson M, Curtis RE, Dores GM, Fraumeni JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, van den Belt-Dusebout AW, Travis LB, Morton LM. Increased stomach cancer risk following radiotherapy for testicular cancer. Br J Cancer 2014;112(1):44-51 Meulepas JM, Ronckers CM, Smets AM, Nievelstein RA, Jahnen A, Lee C, Kieft M, Laméris JS, van Herk M, Greuter MJ, Jeukens CR, van Straten M, Visser O, van Leeuwen FE, Hauptmann M. Leukemia and brain tumors among children after radiation exposure from CT scans: design and methodological opportunities of the Dutch Pediatric CT Study. Eur J Epidemiol 2014 Apr 19 29(4):293-301 Morton LM, Swerdlow AJ, Schaapveld M, Ramadan S, Hodgson DC, Radford J, van Leeuwen FE. Current knowledge and future research directions in treatment-related second primary malignancies. EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer [et al]. 2014;12(1):5. Van Eggermond AM, Schaapveld M, Lugtenburg PJ, Krol AD, de Boer JP, Zijlstra JM, Raemaekers JM, Kremer LC, Roesink JM, Louwman MW, Aleman BM, van Leeuwen FE. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma.

Blood April 2014;124(3):319-327 Van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, Raemaekers JMM, Kremer LCM, Stoval M, Aleman BMP, Van Leeuwen FE, Risk of diabetes mellitus in long-term survivors of Hodgkin lymfoma. J Clin Oncol. 2014 Oct 10;32(29):3257-63 Bastings L, Beerendonk CCM, Westphal JR, Massuger LFAG, Kaal SEJ, van Leeuwen FE, Braat DDM, Peek R. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Human Reproduction Update 2013 19(5):483-506 DeHaasEC,AltenaR,BoezenHM,ZwartN,SmitAJ,BakkerSJ,vanRoonAM,PostmaA,WolffenbuttelBH,HoekstraHJ,vanLeeuwenFE,SleijferDT,GietemaJA. Earlydevelopmentofthemetabolicsyndromeafterchemotherapyfortesticularcancer.AnnOncol2013Mar;24(3):749‐55 Morton LM, Dores GM, Curtis RE, Lynch CF, Stovall M, Hall P, Gilbert ES, Hodgson DC, Storm HH, Børge Johannesen T, Smith SA, Weathers RE, Andersson M, Fossa SD, Hauptmann M, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Pukkala E, Vaalavirta L, Van den Belt-Dusebout AW, Fraumeni JF, Travis LB, Aleman BM, van Leeuwen FE. Stomach cancer risk after treatment for Hodgkin lymphoma. J Clin Oncol 2013; 31(27):3369-3377. Mulder RL, Kremer LC, Hudson MM, Bhatia S, Landier W, Levitt G, Constine LS, Wallace WH, van Leeuwen FE, Ronckers CM, Henderson TO, Dwyer M, Skinner R, Oeffinger KC; International Late Effects of Childhood Cancer Guideline Harmonization Group. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.Lancet Oncol. 2013 Dec;14(13):e621-9. doi: 10.1016/S1470-2045(13)70303-6 Van Dijk IW, Cardous-Ubbink MC, van der Pal HJ, Heinen RC, van Leeuwen FE, Oldenburger F, van Os RM, Ronchers CM, Schouten-van Meeteren AY, Caron HN, Koning CC, Kremer LC. Dose-effect relationships for adverse events after cranial radiation therapy in long-term childhood cancer survivors. Int J Radiat Oncol Biol Phys. 2013;85(3):768-75 Dommering CJ, Marees T, van der Hout AH, Imhof SM, Meijers-Heijboer H, Ringens PJ, van Leeuwen

FE, Moll AC. RB1 mutations and second primary malignancies after hereditary retinoblastoma. Familial Cancer 2012 Jun; 11(2):225-33 Hilbers FS, Boekel NB, van den Broek AJ, van Hien R, Cornelissen S, Aleman BM, 't Veer LJ, van Leeuwen FE, Schmidt MK. Genetic variants in TGFbeta-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer. Radiother Oncol Jan 2012; 102(1):115-21. JonesME,vanLeeuwenFE,HoogendoornWE,MouritsMJ,HollemaH,vanBovenH,PressMF,BernsteinL,SwerdlowAJ. Endometrialcancersurvivalafterbreastcancerinrelationtotamoxifentreatment:pooledresultsfromthreecountries.BreastCancerRes2012Jun12;14(3):R91. KnijnenburgSL,JaspersMW,vanderPalHJ,Schouten‐vanMeeterenAY,BoutsAH,LieverstJA,BökenkampA,KoningCC,OldenburgerF,WildeJC,vanLeeuwenFE,CaronHN,KremerLC. Renaldysfunctionandelevatedbloodpressureinlong‐termchildhoodcancersurvivors.ClinJAmSocNephrol2012Sep;7(9):1416‐27. Ma YP, Van Leeuwen FE, Cooke R, Broeks A, Eciso V, Olver B, Lloyd A, Broderick P, Russell N, Janus C, Answordth A, Houlston S, Swerdlow AJ. FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma. Blood 2012; 119(4):1029-31. Moll AC, Dommering CJ, Bosscha MI, de Graaf P, Kors WA, van Leeuwen FE. Risk factors for the incidence of second cancers in survivors of retinoblastoma with a family history. J Clin Oncol. 2012 Aug 20; 30(24):3028; author reply 3028-9.

Morton LM, Gilbert ES, Hall P, Andersson M, Joensuu H, Vaalavirta L, Dores GM, Stovall M, Holowaty EJ, Lynch CF, Curtis RE, Smith SA, Kleinerman RA, Kaijser M, Storm HH, Pukkala E, Weathers RE, Linet MS, Rajaraman P, Fraumeni JF Jr, Brown LM, van Leeuwen FE, Fossa SD, Johannesen TB, Langmark F, Lamart S, Travis LB, Aleman BM. Risk of treatment-related esophageal cancer among breast cancer survivors. Ann Oncol 2012 Dec; 23(12):3081-91. Overbeek A, van den Berg MH, Kremer LC, van den Heuvel-Eibrink MM, Tissing WJ, Loonen JJ, Versluys B, Bresters D, Kaspers GJ, Lambalk CB, van Leeuwen FE, van Dulmen-den Broeder E; DCOG LATER-VEVO study group. A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. BMC Cancer. 2012 Aug 23; 12:363. Schaapveld M, van den Belt-Dusebout AW, Gietema JA, de Wit R, Horenblas S, Witjes JA, Hoekstra HJ, Kiemeney LA, Louwman WJ, Ouwens GM, Aleman BM, van Leeuwen FE. Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. Br J Cancer 2012 Oct 23; 107(9):1637-43. Sieswerda E, Postma A, van Dalen EC, van der Pal HJ, Tissing WJ, Rammeloo LA, Kok WE, van Leeuwen FE, Caron HN, Kremer LC. The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol 2012 Aug; 23(8):2191-8. Van Nes JG, Fontein DB, Hille ET, Voskuil DW, van Leeuwen FE, de Haes JC, Putter H, Seynaeve C, Nortier JW, van de Velde CJ. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat 2012 Jul; 134(1):267-76. Van der Pal, HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB, Sieswerda E, Oldenburger F, Koning CC, van Leeuwen FE, Caron HN, Kremer LC. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012; 30(13):1429-37. Oeffinger KC, van Leeuwen FE, Hodgson DC. Methods to assess adverse health-related outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev 2011 Oct; 20(10):2022-34. Tromp K, Claessens JJ, Knijnenburg SL, van der Pal HJ, van Leeuwen FE, Caron HN, Beerendonk CC, Kremer LC. Reproductive status in adult male long-term survivors of childhood cancer. Hum Reprod 2011; 26(7):1775-1783 Aleman B, de Bruin M, Dorresteijn L, Krol A, 't Veer M, Boogerd W, van Leeuwen FE. Re: Late Effects From Radiation Therapy: The Hits Just Keep on Coming. J Natl Cancer Inst 2010; 102(8):576-577 Broeks A, Braaf LM, Wessels LF, van de Vijver M, De Bruin ML, Stovall M, Russell NS, Van Leeuwen FE, Van “t Veer. Radiation-associated breast tumors display a distinct gene expression profile. Int J Radiat Oncol Biol Phys 2010; 76(2): 540-7. PUBMED 20117289 Cardous-Ubbink MC, Geenen MM, Schade KJ, Heinen RC, Caron HN, Kremer LCM, Van Leeuwen FE. Hypertension in Long-Term Survivors of Childhood Cancer: A Nested Case-Controle Study. Eur J Cancer 2010; 46(4): 782-90 De Haas EC, Zwart N, Meijer C, Suurmeijer AJ, Van der Meer J, Guchelaar HJ, Hoekstra HJ, van Leeuwen FE, Sleijfer DTh, Boezen HM, Gietema JA. Association of Plasminogen-Activator Inhibitor 1 (PAI-1) 4G/5G Gene Polymorphism with Survival and Chemotherapy-related Vascular Toxicity in Non-seminomatous Testicular Cancer. Cancer 2010 Dec 15; 116(24):5628-36.

Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, van den Berg A, Olver B, Lloyd A, Dobbins SE, Lightfoot T, van Leeuwen FE, Forsti A, Diepstra A, Broeks A, Vijayakrishnan J, Shield L, Lake A, Montgomery D, Roman E, Engert A, von Strandmann EP, Reiners KS, Nolte IM, Smedby KE, Adami HO, Russell NS, Glimelius B, Hamilton-Dutoit S, de Bruin M, Ryder LP, Molin D, Sorensen KM, Chang ET, Taylor M, Cooke R, Hofstra R, Westers H, van Wezel T, van Eijk R, Ashworth A, Rostgaard K, Melbye M, Swerdlow AJ, Houlston RS. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet 2010; 42(12):1126-1130 Fles R, Hoogendoorn WE, Platteel I, Scheerman CE, Leeuw-Mantel G, Mourits MJ, Hollema H, van Leeuwen FE, van Boven HH, Nederlof PM. Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes Cancer 2010; 49(8):699-710 Geenen MM, Bakker PJM, Kremer LCM, Kastelein JJP, van Leeuwen FE. Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatr Blood Cancer 2010; 55(4):690-697 Maduro JH, den Dekker HA, Pras E, de Vries EG, van der Zee AG, Klokman WJ, Reyners AK, van Leeuwen FE, Langendijk JA, de Bock GH, Gietema JA. Cardiovascular Morbidity after Radiotherapy or Chemoradiation in Patients with Cervical Cancer. Int J Radiat Oncol Biol Phys 2010 dec 1; 78(5):1337-44. Marees T, Van Leeuwen FE, Schaapveld M, Imhof SM, De Boer MR, Kors WA, Ringens PJ, Moll AC. Risk of third malignancies and death after a second malignancy in retinoblastoma survivors. Eur. J. Cancer 2010; 46(11):2052-58. Travis L, Beard C, Allan J, Dahl A, Feldman D, Oldenburg J, Daugaard G, Kelly J, Dolan ME, Hannigan R, Constine L, Oeffinger K, Okunieff P, Armstrong G, Wiljer D, Miller R, Gietema J, van Leeuwen FE, Williams J, Nichols C, Einhorn L, Fossa S. Testicular Cancer Survivorship: Research Strategies and Recommendations. J Natl Cancer Inst 2010; 102(15); 1114-30 van den Belt-Dusebout A, Aleman B, Gietema J, de Wit R, Van 't Veer M.B.., Lugtenburg A.D.G., Krol S., van Leeuwen FE. [Long-term complications after the treatment of testis carcinoma and Hodgkin lymphoma]. Ned Tijdschr Geneeskd 2010; 154[A2229]. Van der Pal HJ, Van dalen EC, Hauptmann M, Kok WE, Caron HN, Van den Bos C, Oldenburger F, Koning CC, Van Leeuwen FE, Kremer LC. Cardiac Function in 5-years survivors of childhood cancer; a long-term follow-up study. Arch Int Med 2010; 170:1247-55 Van Dijk I, Oldenburger F, Cardous-Ubbink M, Geenen M, Heinen R, de Kraker J, van Leeuwen FE, van der Pal H, Caron H, Koning C, Kremer L. Evaluation of Late Adverse Events in Long-term Wilms' Tumor Survivors. Int J Rad Onc Biol Phys 2010; 78(2):370-378 Voskuil DW, Van Nes JGH, Junggeburt JMC, Van de Velde CJH, Van Leeuwen FE, De Haes JCJM. Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients. Ann. Oncol 2010; (10);2094-101 De Bruin ML, Burgers S, Baas P, Van ’t Veer MB, Noordijk EM, Louwman MWJ, Zijlstra JM, Van den Berg H, Aleman BPM, Van Leeuwen FE.

Malignant mesothelioma following treatment for Hodgkin’s lymphoma. Blood. 2009; 113(16):3679-81. De Bruin ML, Dorresteijn LDA, Van ‘t Veer MB, Noordijk EM, Van den Berg H, Kapelle AC, Boogerd W, Aleman B, Van Leeuwen FE. Increased risk of Stroke and Transient Ischemic Attack (TIA) in 5-year survivors of Hodgkin's lymphoma.

J. Natl Cancer Inst 2009; 101(13):928 -937. De Bruin ML, Sparidans J, Van ’t Veer MB, Noordijk EM, Louwman MJ, Zijlstra JM, Van den Berg H, Russell N, Broeks A, Baaijens MHA, Aleman B, Van Leeuwen FE. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol sept. 2009: 27(26);4239. Marees T, Van Leeuwen FE, De Boer MR, Imhof SM, Ringens, PH, Moll AC. Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer 2009: 45:3245-53. Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, Van Leeuwen FE. Re: More About Second Cancers After Retinoblastoma. J. Natl Cancer Inst 2009: 102(11): 831-2. Van den Belt-Dusebout AW, Aleman BM, Besseling G, De Bruin ML, Hauptmann M, Van ’t Veer MB, De Wit R, Ribot JG, Noordijk EM, Kerst JM, Gietema JA, Van Leeuwen FE. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009 dec 1; 75(5):1420-9 Broeks, A., Braaf, L.M., Huseinovic, A., Schmidt, M.K., Russel, N.S., Van Leeuwen, F.E., Hogervorst, F.B., and 't Veer L.J. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat 2008;107:243-248. De Bruin ML, Huisbrink J, Kuenen MA, Ouwens GM, Hauptmann M, van ’t Veer MB, Aleman BMP, van Leeuwen FE. Treatment-related risk factors for premature menopause following Hodgkin’s lymphoma. Blood 2008; 111:101-108. De Jong D, Vasmel WLE, De Boer JP, Verhave G, Barbé E, Caparie MK, van Leeuwen FE. Anaplastic large cell lymphoma in women with breast implants. JAMA 2008; 300/17:2030. Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, de Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJE, van Leeuwen FE, and the Comprehensive Cancer Centers' TAMARISK-group* Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat 2008; 112(1):99-108. Hooning MJ, Aleman B, Baaijens MHA, Hauptmann M, Klijn JGM, Noyon R, Stovall M, van Leeuwen FE. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol 2008; 26(34):5561-8. Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of Second Malignancies in Survivors of Retinoblastoma: More Than 40 Years of Follow-Up. J Natl Cancer Inst. 2008; 100(24):1771-9. Schaapveld M, Visser O, Louwman MJ, de Vries EGE, Willemse PHB, Otter R, van der Graaf WTA, Coebergh JWW, van Leeuwen FE. Risk of new primary non-breast cancers following breast cancer treatmen: A Dutch population-based study. J Clin Oncol 2008; 8:1239 - 1246 Schaapveld M, Visser O, Louwman MJ, Willemse PHB, de Vries EGE, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE. The impact of adjuvant therapy on controlateral breast cancer risk and the prognostic significance of controlateral breast cancer: a population-based study in the Netherlands. Breast Cancer Res Treat 2008; 110:189-197. Aleman BMP, van den Belt-Dusebout AW, de Bruin ML, van't Veer MB, Baajijens MHA, de Boer JP, Hart AAM, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109(5):1878-1886.

Aleman BMP, van Leeuwen FE. Are we improving the long-term burden of Hodgkin’s lymphoma patients with modern treatment?. Hematol Oncol Clin North Am 2007; 21:961-975. Borger JH, Hooning MJ, Boersma LJ, Snijder-Keilholz A, Aleman BMP, Lintzen E, van Brussel S, van der Toorn PP, Alwhouhayb M, van Leeuwen FE. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys 2007; 69:1131-1138. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus JH, Hogervorst FBL, Schmidt MK, Klijn JGM, Russel NS, van Leeuwen FE, van’t Veer LJ. Identification of woman with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Research 2007; 9(2):R26. Cardous-Ubbink MC, Heinen RC, Bakker PJ, van den Berg H, Oldenburger F, Caron HN, Voute PA, van Leeuwen FE. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer 2007; 43(2):351-362. Geenen MM, Cardous-Ubbink MC, Kremer LCM, van den Bos C, van der Pal HJH, Heinen RC, Jaspers MWM, Koning CCE, Oldenburger F, Langeveld NE, Hart AAM, Bakker PJM, Caron HN, van Leeuwen FE. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007; 297(24):2705-2715. Hooning MJ, Botma A, Aleman BMP, Baaijens MHA, Bartelink H, Klijn JGM, Taylor CW, van Leeuwen FE: Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99(5):365-375. Jaspers MW, van den Bos C, Heinen RC, Bakker PJ, Geenen MM, Kremer LC, van Leeuwen FE, Caron HN. Development of a national protocol to screen Dutch cancer survivors on late cancer treatment effects. Int J Med Inform 2007; 76(4):297-305. van den Belt-Dusebout AW1, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007 Oct 1;25(28):4370-8 Vrieling A, Rookus MA, Kampman E, Bonfrer JM, Korse CM, van Doorn J, Lampe JW, Cats A, Witteman BJ, van Leeuwen FE, van't Veer LJ, Voskuil DW. Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk. J Nutr 2007; 137:379-383. Hooning MJ, Dorresteijn LD, Aleman BMP, Kappelle AC, Klijn JG, Boogerd W, van Leeuwen FE. Decreased risk of stroke among 10-year survivors of breast cancer. J Clin Oncol 2006; 24(34):5388-5394. HooningMJ,AlemanBMP,vanRosmalenAJM,KuenenMA,KlijnJGM,vanLeeuwenFE. Cause‐specificmortalityinlong‐termsurvivorsofbreastcancer:A25‐yearfollow‐upstudy.IntJRadiatOncolBiolPhys2006;64(4):1081‐1091. Merks JH, Ozgen HM, Cluitmans TL, van der Burg-van Rijn JM, Cobben JM, van Leeuwen FE, Hennekam RC. Normal values for morphological abnormalities in school children. Am J Med Genet A 2006; 140(19):2091-2109. Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC. Risk of second cancer after treatment of aggressive Non-Hodgkin’s lymphoma; an EORTC cohort study.

Haematologica 2006; 91(11):1481-1488. Moser EC, Noordijk EM, van Leeuwen FE, Le Cessie S, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC. Long-term risk of cardiovascular disease after treatment for aggresive Non-Hodgkin’s lymphoma. Blood 2006; 107(7):2912-2919. Van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PTR, Schimmel EC, Aleman BMP, van Leeuwen FE. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24(3):467-475. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, Van't Veer MB, Joensuu T, Storm H, Stovall M, Boice JD Jr, Gilbert E, Gail MH. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97(19):1428-37. Hill DA, Gilbert E, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer M, Storm H, Pukkala E, Stovall M, Curtis RE, Allan JM, Boice JD, Travis LB. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005; 106(10):3358-65. In der Maur CD, Klokman WJ, van Leeuwen FE, Tan IB, Rutgers EJTh, Balm AJM. Increased risk of breast cancer development after diagnosis of salivary gland tumor. Eur J Cancer. 2005; 41(9):1311-5. Van der Pal HJH, van Dalen EC, Kremer LCM, Bakker PJM, van Leeuwen FE. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: A systematic review. Cancer Treat Rev. 2005; 31(3):173-85. Aleman BMP, Russell NS, Bartelink H, van Leeuwen FE. Radiation therapy in the Treatment of Hodgkin's Disease--Do You See What I See? [letter,reply]. J Natl Cancer Inst 2004; 96(3):235-236. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, Russell NS, van't Veer LJ. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004; 83(1):91-3. Cardous-Ubbink MC, Heinen RC, Langeveld NE, Bakker PJM, Voûte PA, Caron HN, van Leeuwen FE. Long-term cause-specific mortality among five-year surv\ivor childhood cancer. Pediatric Blood and Cancer 2004; 42(7):563-573. Hoogendoorn WE, Hollema H, Nederlof PM, van Boven HH, Mourits MJ, van Leeuwen FE. The Tamarisk-study, a cohort study of the clinicopathological and molecular characteristics, and the prognosis of uterine malignancies after tamoxifen. Eur J Cancer Suppl 2004; 2:88. Ronckers CM, Verduijn PG, Land CE, Hayes RB, Stovall M, van Leeuwen FE. [No convincing evidence for a causal relationship between childhood nasopharyngeal radium irradiation and head-neck tumors or hormone-related disorders later in life; a retrospective cohort study]. Ned Tijdschr Geneeskd 2004; 148(36):1775-1780 Aleman BMP, Van den Belt-Dusebout AW, Klokman WJ, Van ‘t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003; 21(18):3431-3439.

Gilbert ES, Stovall M, Gospodarowicz M, van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, Lynch CF, Curtis RE, Holowaty E, Storm H, Pukkala E, van't Veer MB, Fraumeni JF, Boice JD Jr, Clarke EA, Travis LB. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003; 159(2):161-173 Kaas R, Peterse JL, Hart AA, Voogd AC, Rutgers EJ, van Leeuwen FE. The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer. Br J Cancer 2003;88(5): 707-710. Moll AC, Imhof SM, Schouten-van Meeteren AY, Boers M, van Leeuwen F, Hofman P. Chemoreduction for retinoblastoma. Arch Ophthalmol 2003; 121(10):1513. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van ’t Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD, Gilbert E. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin’s disease. JAMA 2003; 290(4):465-475. Van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, Van ‘t Veer MB, Noordijk EM, Crommelin MA, Aleman BMP, Broeks A, Gospodarowicz M, Travis LB, Russell NS. Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin's Disease. J Natl Cancer Inst 2003; 95(13):971-980. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van 't Veer MB, Stovall M, Gospodarowicz M, Travis LB. Second salignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20(16):3484-3494. Dorresteijn LD, Kappelle AC, Boogerd W, Klokman WJ, Balm AJ, Keus RB, van Leeuwen FE, Bartelink H. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 2002; 20(1):282-288. Ronckers CM, Land CE, Hayes RB, Verduijn PG, Stovall M, van Leeuwen FE. Late health effects of childhood nasopharyngeal radium irradiation: nonmelanoma skin cancers, benign tumors, and hormonal disorders. Pediatr Res 2002; 52(6):850-858 Ronckers CM, van Leeuwen FE, Hayes RB, Verduijn PG, Stovall M, Land CE. Cancer incidence after nasopharyngeal radium irradiation. Epidemiology 2002; 13(5):552-560. Van Leeuwen FE, Hooning MJ, Aleman BMP, Travis LB. Second cancer risk following breast cancer.European Journal of Cancer 2002; 38(3):S28-S30. Noorda EM, Somers R, van Leeuwen FE, Vulsma T, Behrendt H. The Dutch Late Effects Study Group. Adult height and age at menarche in childhood cancer survivors. Eur J Cancer 2001;37:605-612. Ronckers CM, Land CE, Verduijn PG, Hayes RB, Stovall M, van Leeuwen FE. Cancer mortality after nasopharyngeal radium irradiation in the Netherlands; a cohort study. J Nat Cancer Inst 2001;93(13):1021-1027 Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF. van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease.

J Natl Cancer Inst 2002;94(3):182-192. Aleman BM, Klokman WJ, van Leeuwen FE. [Second primary tumors in patients treated at an early age for Hodgkin’s disease, consequences for the follow-up]. Ned Tijdsch Geneeskd 2000; 144(32): 1517-1520. Bergman L, Beelen MLR, Gallee MPW, Hollema H, Benraadt J, van Leeuwen FE, the Comprehensive Cancer Centres’ ALERT Group. Risk and prognosis of endometrial cancer following tamoxifen for breast cancer. Lancet 2000; 356: 881-887. Broeks A, Urbanus JHM, Floore AN, Dahler EC, Klijn JGM, Rutgers EJT, Devilee P, Russell NS, van Leeuwen FE, Van ‘t Veer LJ. Classical ATM germline mutations contribute to breast cancer susceptibility. Am J Hum Genet 2000; 66: 494-500. Broeks A, Russell NS, Floore AN, Urbanus JHM, Dahler EC, Van ‘t Veer MB, Hagenbeek A, Noordijk EM, Crommelin MA, van Leeuwen FE, Van ‘t Veer LJ. Increased risk of breast cancer following irradiation for Hodgkin’s disease is not a result of ATM germline mutations. Int J Radiat Biol 2000; 76: 693-698. Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, Joensuu T, van Leeuwen FE, Van ’t Veer MB, Curtis RE, Holowaty EJ, Andersson M, Wiklund T, Gospodarowicz M, Travis LB. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18: 2435-2443. Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, Curtis RE, Kohler BA, Wiklund T, Storm H, Holowaty E, Hall P, Pukkala E, Sleijfer DT, Clarke EA, Boice JD Jr, Stovall M, Gilbert E. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000; 92: 1165-1171. Van Leeuwen FE, Klokman WJ, Van ‘t Veer MB, Hagenbeek A, Krol ADG, Vetter UAO, Schaapveld M, Van Heerde P, Burgers JMV, Somers R, Aleman BMP. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000;18: 487-497. Van Leeuwen FE, Klokman WJ, Aleman. Second malignancies in Hodgkin’s disease [letter, reply]. J Clin Oncol 2000; 18: 2186-2187. Kahn MA, Travis LB, Lynch CF, Soini Y, Hruszkewycz AM, Delgado RM, Holowaty EJ, van Leeuwen FE, Glimelius B, Stovall M, Boice Jr JD, Tarone RE, Bennett WP. p53 Mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers and Prevention 1998; 7: 397-403. Van Leeuwen FE, Stiggelbout AM, Van den Belt-Dusebout AW, Noyon R, Eliel MR, Van Kerckhoff EHM, Delemarre JFM, Somers R. Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J Clin Oncology. Classic Papers and Current Comments 1998; 2: 460-468. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF, Boice JD Jr. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89: 1429-1439. Bergman L, Benraadt J, van Leeuwen FE. Tamoxifen: balancing risks and benefits. Neth J Med 1996; 49: 228-234.

Van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. In: Löwenberg B (ed). Baillière Clinical Haematology: international practice and research. Acute myelogenous leukaemia and myelodysplasia (vol 9, no 1). London: Ballière Tindall, 1996: 57-85. Van Leeuwen FE, Klokman WJ. Re: Smoking, treatment for Hodgkin's disease, and subsequent lung cancer risk [letter,reply]. J Natl Cancer Inst 1996; 88: 209. De Benedetti VMG, Travis LB, Welsh JA, van Leeuwen FE, Stovall M, Clarke EA, Boice Jr JD, Bennett WP. p53 Mutations in lung cancer following radiation therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers and Prevention 1996; 5: 93-98. Van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, Van den Belt-Dusebout AW, Noyon R, Boice Jr JD, Burgers MV, Somers R. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995; 87: 1530-1537. Van Halteren HK, Taal BG, Van Tinteren H, van Leeuwen FE. Risk factors for the development of oesophageal cancer as a second primary tumour. Eur J Cancer 1995; 31A: 1836-1839. Travis LB, Curtis RE, Glimelius B, Holowaty E, van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, Gospodarowicz M, Wacholder S, Inskip P, Tucker MA, Boice Jr JD. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87: 524-530. Bergman L, Van Dongen JA, Van Ooijen B, van Leeuwen FE. Should tamoxifen be a primary choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat 1995; 34: 77-83. Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Chin-Yang Li, Banks PM, Gospodarowicz MK, Adami J, Wacholder S, Inskip PD, Tucker MA, Boice Jr JD. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 1994; 86: 1450-1457. Van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, Van den Belt-Dusebout AW, Van Kerckhoff EHM, Van Heerde P, Somers R. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312-325. Van Leeuwen FE, Chorus AMJ, Van den Belt-Dusebout AW, Hagenbeek A, Noyon R, Van Kerckhoff EHM, Pinedo HM, Somers R. Leukemia risk following Hodgkins's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, numbers of episodes of chemotherapy and bone marrow damage. J Clin Oncol 1994; 12: 1063-1073. Van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimbrere CHF, Otter R, Schouten LJ, Damhuis RAM, Bontenbal M, Diepenhorst FW, Van den Belt-Dusebout AW, Van Tinteren H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448-452. Van Leeuwen FE, Stiggelbout AM, Van den Belt-Dusebout AW, Noyon R, Eliel MR, Van Kerckhoff EHM, Delemarre JFM, Somers R. Second cancer risk following testicular cancer: a follow-up study of 1909 patients [letter, reply]. J Clin Oncol 1993; 11: 2286-2287. Travis LB, Curtis RE, Glimelius B, Holowaty E, van Leeuwen FE, Lynch CF, Adami J, Gospodarowicz M, Wacholder S, Inskip P, Tucker MA, Fraumeni Jr JF, Boice Jr JD. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85: 1932-1937.

Van Leeuwen FE, Stiggelbout AM, Van den Belt-Dusebout AW, Noyon R, Eliel MR, Van Kerckhoff EHM, Delemarre JFM, Somers R. Second cancer risk following testicular cancer: A follow-up study of 1909 patients. J Clin Oncol 1993; 11: 415-424. Kaldor JM, Day NE, Clarke EA, van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pedersen D, Band P, Assouline D, Koch M, Choi W, Prior P, Blair V, Langmark F, Kirn VP, Neal F, Peters D, Pfeiffer R, Karjalainen S, Cuzich J, Sutcliffe SB, Somers R, Pellae-Cosset B, Pappagallo GL, Fraser P, Storm H, Stovall M. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322: 7-13. Van Leeuwen FE, Somers R, Taal BG, Van Heerde P, Coster B, Dozeman T, Huisman SF, Hart AAM. Increased risk of lung cancer, non-Hodgkin lymphoma and leukemia following Hodgkin's disease. J Clin Oncol 1989;7(8):1046-1058. Burgers JM, el Sharouni SY, van Leeuwen FE, Somers R, Hart AA. [Hodgkin’s disease: the effect of age on prognosis] Ned. Tijdschr Geneeskd 1988; 132(29):1354-1357. Somers R, van Leeuwen FE, Taal bG, van Heerde P, Coster B, Hart AA. [Second tumors following treatment of Hogkin’s disease]. Ned Tijdsch Geneeskd 1988; 132(20):1358-1362. Van der Velden JW, Van Putten WL, Guinee VF, Pfeiffer R, Schmidt C, van Leeuwen FE, Van der Linden EAM, McVie JG, Vardomskaya I, Klimenkov A, Lane W, Gomez I, Durand M, Lagarde C, Hagemeister FB, Hagenbeek A, Eghbali H. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer 1988; 42: 252-255 Van Leeuwen FE, Somers R, Hart AAM et al. Splenectomy in Hodgkin's disease and second leukemias. Lancet 1987; 2: 210-11.

II. Etiology of breast cancer and other hormone-related cancers Henderson A, Osorio A, Jakubowska A, Gerdes A-M, Antoniou AC, Arver B, Buecher B, Brewer C, Nogues C, Dommering CJ, Singer CF, Engel C, Evans DG, Barrowdale D, Goldgar D, Frost D, Eccles D, Easton DF, Olah E, Luporsi E, John EM, van Leeuwen FE, Olsson H, Andrulis IL, Cook J, Simard J, Oosterwijk JC, McDonald JA, Moretta-Serra J, Hopper JL, Ong K-r, Kast K, Gladieff L, Foretova L, Izatt L, Ausems MGEM, Navratilova M, Roos-Blom M-J, Daly M, Terry MB, Rookus MA, Friedlander M, Kriege M, Ahmed M, Morrison PJ, Schmutzler RK, Milne RL, Buys SS, McLachlan SA, Mooij TM, Caldes T, Mari V, Tan Y, Liao Y, Andrieu N. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum. 2019;2(4). van den Broek AJ, Schmidt MK, van 't Veer LJ, Oldenburg HSA, Rutgers EJ, Russell NS, Smit V, Voogd AC, Koppert LB, Siesling S, Jobsen JJ, Westenend PJ, van Leeuwen FE, Tollenaar R. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. Annals of surgery. 2018;doi: 10.1097/SLA.0000000000002804. [Epub ahead of print]. Schrijver LH, Olsson H, Phillips K, Terry MB, Goldgar DE, Kast K, Engel C, Mooij TM, Adlard J, Barrowdale D, Davidson R, Eeles R, Ellis S, Evans DG, Frost D, Izatt L, Porteous ME, Side LE, Walker L, Berthet P, Bonadona V, Leroux D, Mouret-Fourme E, Venat-Bouvet L, Buys SS, Southey MC, John EM, Chung WK, Daly MB, Bane A, van Asperen CJ, Gómez Garcia EB, Mourits MJE, van Os TAM, Roos-Blom M, Friedlander ML, McLachlan S, Singer CF, TanYY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes A, Caldes T, SimardJ, Olah E, Jakubowska A, ArverB, Osorio A, Noguès C, Andrieu N, Easton DF, van Leeuwen FE, Hopper JL, Milne RL, Antoniou AC, Rookus MA; on behalf of EMBRACE, GENEPSO, BCFR, HEBON, kConFab and IBCCS. Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study. JNCI 2018; In press Derks-Smeets IAP*, Schrijver LH*, de Die-Smulders CEM, Tjan-Heijnen VCG, van Golde RJT, Smits LJ, Caanen B, van Asperen C, AusemsM, Collée M, van Engelen K, Kets CM, van der Kolk L, Oosterwijk JC, van Os T, HEBON, Rookus MA, van Leeuwen FE**, Gómez García EB** * shared first authors, ** shared last authors. Ovarian stimulation for IVF and risk of primary breast

cancer in BRCA1/2 mutation carriers. BJC 2018; In press. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, Brca, Consortium BC, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017;317(23):2402 Caanen MR, Schouten NE, Kuijper EAM, van Rijswijk J, van den Berg MH, van Dulmen-den Broeder E, Overbeek A, van Leeuwen FE, van Trotsenburg M, Lambalk CB. Effects of long-term exogenous testosterone administration on ovarian morphology, determined by transvaginal (3D) ultrasound in female-to-male transsexuals. Hum Reprod. 2017:1. Engelhardt EG, van den Broek AJ, Linn SC, Wishart GC, Rutgers EJT, van de Velde AO, Smit VTHBM, Voogd AC, Siesling S, Brinkhuis M, Seynaeve C, Westenend PJ, Stiggelbout AM, Tollenaar RAEM, van Leeuwen FE, van 't Veer LJ, Ravdin PM, Pharaoh PDP, Schmidt MK. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. European Journal of Cancer. 2017;78:37. Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ, Jager A, Voogd AC, van Leeuwen FE, van 't Veer LJ. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. J Natl Cancer Inst. 2017;109(8). Elshof LE, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J, Schaapveld M. Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Annals of surgery. 2017. Elshof LE, Schaapveld M, Rutgers EJ, Schmidt MK, de Munck L, van Leeuwen FE, Wesseling J. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study. Breast Cancer Res. 2017;19:26. Verloop J, van Leeuwen FE, Helmerhorst TJM, de Kok IMCM, van Erp EJM, van Boven HH, Rookus MA. Risk of cervical intra-epithelial neoplasia and invasive cancer of the cervix in DES daughters. Gynecol Oncol. 2017;144(2):305 Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J. Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Res Treat. 2017;161(2):389. Abubakar M, Howat WJ, Daley F, Zabaglo L, McDuffus LA, Blows F, Coulson P, Raza Ali H, Benitez J, Milne R, Brenner H, Stegmaier C, Mannermaa A, Chang-Claude J, Rudolph A, Sinn P, Couch FJ, Tollenaar RA, Devilee P, Figueroa J, Sherman ME, Lissowska J, Hewitt S, Eccles D, Hooning MJ, Hollestelle A, Wm Martens J, Hm van Deurzen C, Investigators k, Bolla MK, Wang Q, Jones M, Schoemaker M, Broeks A, van Leeuwen FE, Van't Veer L, Swerdlow AJ, Orr N, Dowsett M, Easton D, Schmidt MK, Pharoah PD, Garcia-Closas M. High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. The journal of pathology Clinical research. 2016;2(3):138. Abubakar M, Orr N, Daley F, Coulson P, Ali HR, Blows F, Benitez J, Milne R, Brenner H, Stegmaier C, Mannermaa A, Chang-Claude J, Rudolph A, Sinn P, Couch FJ, Devilee P, Tollenaar RAEM, Seynaeve C, Figueroa J, Sherman ME, Lissowska J, Hewitt S, Eccles D, Hooning MJ, Hollestelle A, Martens JWM, van Deurzen CHM, Investigators k, Bolla MK, Wang Q, Jones M, Schoemaker M, Wesseling J, van Leeuwen FE, Van ‘t Veer L, Easton D, Swerdlow AJ, Dowsett M, Pharoah PD, Schmidt MK, Garcia-Closas M. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016;18(1):104

Derks MG, de Glas NA, Bastiaannet E, de Craen AJ, Portielje JE, van de Velde CJ, van Leeuwen FE, Liefers G-J. Physical Functioning in Older Patients With Breast Cancer: A Prospective Cohort Study in the TEAM Trial. Oncologist. 2016;21(8):946 Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W. Comparative cistromics reveals genomic cross-talk between FOXA1 and ERα in tamoxifen-associated endometrial carcinomas. Cancer Res. 2016;76(13):3773 Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Res Treat. 2016;159(3):553. Van den Broek AJ, van ’t Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VTHBM, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RAEM, van Leeuwen FE*, Schmidt MK* (* shared senior authers). Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol. 2016;34(5):409 Heemskerk-Gerritsen AM, Rookus MA, Aalfs CM, Ausems MGEM, Collée JM, Jansen L, Kets CM, Keymeulen KBMI, Koppert LB, Meijers-Heijboer HEJ, Mooij TM, Tollenaar RAEM, Vasen HFA, Hebon, Hooning MJ, Seynaeve C. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. Int J Cancer 2015;136(3):668-77 Heemskerk-Gerritsen BAM, Seynaeve C, Van Asperen C, Ausems JM, Collee JM, Van Doorn HC, Gomez Garcia EB, Kets CM, Van Leeuwen FE, Meijers-Heijboer HEJ, Mourits MJE, Van Os TAM, Vasen HFA, Verhoef S, Rookus MA, Hooning MJ, for the Hereditary Breast Ovarian Cancer Research Group Netherlands. Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction J Natl Cancer Inst 2015;107(3):djv033 Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS, BCFR, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Andrés-Conejero R, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, EMBRACE., Douglas F, Cook J, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Cole T, Godwin AK, Isaacs C, Claes K, De Leeneer K, Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Schmutzler RK, Preisler-Adams S, Markov NB, Wang-Gohrke S, de Pauw A, Lefol C, Lasset C, Leroux D, Rouleau E, Damiola F, Collaborators GS, Dreyfus H, Barjhoux L, Golmard L, Uhrhammer N, Bonadona V, Sornin V, Bignon YJ, Carter J, Van Le L, Piedmonte M, DiSilvestro PA, de la Hoya M, Caldes T, Nevanlinna H, Aittomäki K, Jager A, van den Ouweland AM, Kets CM, Aalfs CM, van Leeuwen FE, Hogervorst FB, Meijers-Heijboer HE, HEBON, Oosterwijk JC, van Roozendaal KE, Rookus MA, Devilee P, van der Luijt RB, Olah E, Diez O, Teulé A, Lazaro C, Blanco I, Del Valle J, Jakubowska A, Sukiennicki G, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Agnarsson BA, Maugard C, Amadori A, Montagna M, Teixeira MR, Spurdle AB, Foulkes W, Olswold C, Lindor N, Pankratz VS, Szabo CI, Lincoln A, Jacobs L, Corines M, Robson M, Vijai J, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Greene MH, Mai PL, Rennert G, Imyanitov EN, Mulligan AM, Glendon G, Andrulis IL, Tchatchou S, Toland AE, Pedersen IS, Thomassen M, Kruse TA, Jensen UB, Caligo MA, Friedman E, Zidan J, Laitman Y, Lindblom A, Melin B, Arver B, Loman N, Rosenquist R, Olopade O, Nussbaum RL, Ramus SJ, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Mitchell G, Karlan BY, Lester J, Orsulic S, Stoppa-Lyonnet D, Thomas G, Simard J, Couch FJ, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC, Mazoyer S, Phelan CM, Sinilnikova OM, Cox DG. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 2015;17(1):61. Van den Broek AJ, Schmidt MK, Van ’t Veer L, Tollenaar R, Van Leeuwen FE. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review wit meta-analysis. Plos One 2015;10(3):e0120189

Van den Broek AJ, de Ruiter K, van 't Veer LJ, Tollenaar RAEM, van Leeuwen FE, Verhoef S, Schmidt MK. Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. Eur J Hum Genet 2015;23(5):588-95 Brohet R, Velthuizen M, Hogervorst F, Meijers-Heijboer H, Seynaeve C, Collée M, Verhoef S, Ausems M, Hoogerbrugge N, van Asperen C, Gómez Garcia E, Menko F, Oosterwijk J, Devilee P, Veer L, van Leeuwen FE, Easton D, Rookus M, Antoniou A, HEBON Resource. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet 2014;51(2):98-107 Drukker CA, Schmidt MK, Rutgers EJ, Cardoso F, Kerlikowske K, Esserman LJ, van Leeuwen FE, Pijnappel RM, Slaets L, Bogaerts J, van ’t Veer LJ. Mammografphic screening detects low-risk tumor biology breast cancers. Breast Cancer Res Treat 2014;144(1):103-11 Pijpe A, Slottje P, van Pelt C, Stehmann F, Kromhout H, Van Leeuwen FE, Vermeulen RC, Rookus MA. The Nightingale study: rationale, study design and baseline characteristics of a prospective study of shift work and breast cancer risk among nurses. BMC Cancer 2014; 14:47 Vos JR, Teixeira N, van der Kolk DM, Mourits MJE, Rookus MA, van Leeuwen FE, Collée M, van Asperen CJ, Mensenkamp AR, Ausems MGEM, van Os TAM, Meijers-Heijboer HEJ, Gómez-Garcia EB, Vasen HF, Brohet RM, Breast obotH, Netherlands OCRG, van der Hout AH, Jansen L, Oosterwijk JC, de Bock GH. Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands. Cancer Epidemiol Biomarkers Prev 2014;23(11):2482-91 Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK; SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ; GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmalm M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, KonLindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A; BCFR, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkowicz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC; CIMBA. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genet 2013; 9(3): e1003212. doi:10.1371/journal.pgen.1003212

Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, Soucy P, Sinilnikova OM, Pankratz VS, Wang X, Eldridge RC, Tessier DC, Vincent D, Bacot F, Hogervorst FB, Peock S, Stoppa-Lyonnet D; KConFab Investigators, Peterlongo P, Schmutzler RK, Nathanson KL, Piedmonte M, Singer CF, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Blanco I, Greene MH, Garber J, Weitzel JN, Andrulis IL, Goldgar DE, D'Andrea E, Caldes T, Nevanlinna H, Osorio A, van Rensburg EJ, Arason A, Rennert G, van den Ouweland AM, van der Hout AH, Kets CM, Aalfs CM, Wijnen JT, Ausems MG; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Jacobs C, Adlard J, Tischkowitz M, Porteous ME, Damiola F; GEMO Study Collaborators, Golmard L, Barjhoux L, Longy M, Belotti M, Ferrer SF, Mazoyer S, Spurdle AB, Manoukian S, Barile M, Genuardi M, Arnold N, Meindl A, Sutter C, Wappenschmidt B, Domchek SM, Pfeiler G, Friedman E, Jensen UB, Robson M, Shah S, Lazaro C, Mai PL, Benitez J, Southey MC, Schmidt MK, Fasching PA, Peto J, Humphreys MK, Wang Q, Michailidou K, Sawyer EJ, Burwinkel B, Guénel P, Bojesen SE, Milne RL, Brenner H, Lochmann M; GENICA Network, Aittomäki K, Dörk T, Margolin S, Mannermaa A, Lambrechts D, Chang-Claude J, Radice P, Giles GG, Haiman CA, Winqvist R, Devillee P, García-Closas M, Schoof N, Hooning MJ, Cox A, Pharoah PD, Jakubowska A, Orr N, González-Neira A, Pita G, Alonso MR, Hall P, Couch FJ, Simard J, Altshuler D, Easton DF, Chenevix-Trench G, Antoniou AC, Offit K Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genet 2013; 9(3): e1003173. doi:10.1371/journal.pgen.1003173 BojesenSE,PooleyKA,JohnattySE,BeesleyJ,MichailidouK,TyrerJP,EdwardsSL,PickettHA,ShenHC,SmartCE,HillmanKM,MaiPL,LawrensonK,StutzMD,LuY,KarevanR,WoodsN,JohnstonRL,FrenchJD,ChenX,WeischerM,NielsenSF,MaranianMJ,GhoussainiM,AhmedS,BaynesC,BollaMK,WangQ,DennisJ,McGuffogL,BarrowdaleD,LeeA,HealeyS,LushM,TessierDC,VincentD,BacotF;AustralianCancerStudy;AustralianOvarianCancerStudy;KathleenCuninghamFoundationConsortiumforResearchintoFamilialBreastCancer(kConFab);GeneEnvironmentInteractionandBreastCancer(GENICA);SwedishBreastCancerStudy(SWE‐BRCA);HereditaryBreastandOvarianCancerResearchGroupNetherlands(HEBON);EpidemiologicalstudyofBRCA1&BRCA2MutationCarriers(EMBRACE);GeneticModifiersofCancerRiskinBRCA1/2MutationCarriers(GEMO),VergoteI,LambrechtsS,DespierreE,RischHA,González‐NeiraA,RossingMA,PitaG,DohertyJA,AlvarezN,LarsonMC,FridleyBL,SchoofN,Chang‐ClaudeJ,CicekMS,PetoJ,KalliKR,BroeksA,ArmasuSM,SchmidtMK,BraafLM,WinterhoffB,NevanlinnaH,KonecnyGE,LambrechtsD,RogmannL,GuénelP,TeomanA,MilneRL,GarciaJJ,CoxA,ShridharV,BurwinkelB,MarmeF,HeinR,SawyerEJ,HaimanCA,Wang‐GohrkeS,AndrulisIL,MoysichKB,HopperJL,OdunsiK,LindblomA,GilesGG,BrennerH,SimardJ,LurieG,FaschingPA,CarneyME,RadiceP,WilkensLR,SwerdlowA,GoodmanMT,BrauchH,Garcia‐ClosasM,HillemannsP,WinqvistR,DürstM,DevileeP,RunnebaumI,JakubowskaA,LubinskiJ,MannermaaA,ButzowR,BogdanovaNV,DörkT,PelttariLM,ZhengW,LeminenA,Anton‐CulverH,BunkerCH,KristensenV,NessRB,MuirK,EdwardsR,MeindlA,HeitzF,MatsuoK,duBoisA,WuAH,HarterP,TeoSH,SchwaabI,ShuXO,BlotW,HosonoS,KangD,NakanishiT,HartmanM,YatabeY,HamannU,KarlanBY,SangrajrangS,KjaerSK,GaborieauV,JensenA,EcclesD,HøgdallE,ShenCY,BrownJ,WooYL,ShahM,AzmiMA,LubenR,OmarSZ,CzeneK,VierkantRA,NordestgaardBG,FlygerH,VachonC,OlsonJE,WangX,LevineDA,RudolphA,WeberRP,Flesch‐JanysD,IversenE,NickelsS,SchildkrautJM,SilvaIdosS,CramerDW,GibsonL,TerryKL,FletcherO,VitonisAF,vanderSchootCE,PooleEM,HogervorstFB,TworogerSS,LiuJ,BanderaEV,LiJ,OlsonSH,HumphreysK,OrlowI,BlomqvistC,Rodriguez‐RodriguezL,AittomäkiK,SalvesenHB,MuranenTA,WikE,BrouwersB,KrakstadC,WautersE,HalleMK,WildiersH,KiemeneyLA,MulotC,AbenKK,Laurent‐PuigP,AltenaAM,TruongT,MassugerLF,BenitezJ,PejovicT,PerezJI,HoatlinM,ZamoraMP,CookLS,BalasubramanianSP,KelemenLE,SchneeweissA,LeND,SohnC,Brooks‐WilsonA,TomlinsonI,KerinMJ,MillerN,CybulskiC,HendersonBE,MenkiszakJ,SchumacherF,WentzensenN,LeMarchandL,YangHP,MulliganAM,GlendonG,EngelholmSA,KnightJA,HøgdallCK,ApicellaC,GoreM,TsimiklisH,SongH,SoutheyMC,JagerA,denOuwelandAM,BrownR,MartensJW,FlanaganJM,KriegeM,PaulJ,MargolinS,SiddiquiN,SeveriG,WhittemoreAS,BagliettoL,McGuireV,StegmaierC,SiehW,MüllerH,ArndtV,LabrècheF,GaoYT,GoldbergMS,YangG,DumontM,McLaughlinJR,HartmannA,EkiciAB,BeckmannMW,PhelanCM,LuxMP,Permuth‐WeyJ,PeisselB,SellersTA,FicarazziF,BarileM,ZiogasA,AshworthA,Gentry‐MaharajA,JonesM,RamusSJ,OrrN,MenonU,PearceCL,BrüningT,PikeMC,KoYD,LissowskaJ,FigueroaJ,KupryjanczykJ,ChanockSJ,Dansonka‐MieszkowskaA,Jukkola‐VuorinenA,RzepeckaIK,PylkäsK,BidzinskiM,KauppilaS,HollestelleA,SeynaeveC,TollenaarRA,DurdaK,JaworskaK,HartikainenJM,KosmaVM,KatajaV,AntonenkovaNN,LongJ,ShrubsoleM,Deming‐HalversonS,LophatananonA,SiriwanarangsanP,Stewart‐BrownS,DitschN,LichtnerP,SchmutzlerRK,ItoH,IwataH,TajimaK,TsengCC,StramDO,vandenBergD,YipCH,IkramMK,TehYC,CaiH,LuW,SignorelloLB,CaiQ,NohDY,YooKY,MiaoH,IauPT,TeoYY,McKayJ,ShapiroC,AdemuyiwaF,FountzilasG,HsiungCN,YuJC,HouMF,HealeyCS,LuccariniC,PeockS,Stoppa‐LyonnetD,PeterlongoP,RebbeckTR,PiedmonteM,SingerCF,FriedmanE,ThomassenM,OffitK,HansenTV,NeuhausenSL,SzaboCI,BlancoI,GarberJ,NarodSA,WeitzelJN,MontagnaM,OlahE,GodwinAK,YannoukakosD,GoldgarDE,CaldesT,ImyanitovEN,TihomirovaL,ArunBK,CampbellI,MensenkampAR,vanAsperenCJ,vanRoozendaalKE,Meijers‐HeijboerH,ColléeJM,

OosterwijkJC,HooningMJ,RookusMA,vanderLuijtRB,OsTA,EvansDG,FrostD,FinebergE,BarwellJ,WalkerL,KennedyMJ,PlatteR,DavidsonR,EllisSD,ColeT,Bressac‐dePailleretsB,BuecherB,DamiolaF,FaivreL,FrenayM,SinilnikovaOM,CaronO,GiraudS,MazoyerS,BonadonaV,Caux‐MoncoutierV,Toloczko‐GrabarekA,GronwaldJ,ByrskiT,SpurdleAB,BonanniB,ZaffaroniD,GianniniG,BernardL,DolcettiR,ManoukianS,ArnoldN,EngelC,DeisslerH,RhiemK,NiederacherD,PlendlH,SutterC,WappenschmidtB,BorgA,MelinB,RantalaJ,SollerM,NathansonKL,DomchekSM,RodriguezGC,SalaniR,KaulichDG,TeaMK,PaluchSS,LaitmanY,SkytteAB,KruseTA,JensenUB,RobsonM,GerdesAM,EjlertsenB,ForetovaL,SavageSA,LesterJ,SoucyP,KuchenbaeckerKB,OlswoldC,CunninghamJM,SlagerS,PankratzVS,DicksE,LakhaniSR,CouchFJ,HallP,MonteiroAN,GaytherSA,PharoahPD,ReddelRR,GoodeEL,GreeneMH,EastonDF,BerchuckA,AntoniouAC,Chenevix‐TrenchG,DunningAM. MultipleindependentvariantsattheTERTlocusareassociatedwithtelomerelengthandrisksofbreastandovariancancer.NatGenet2013Apr;45(4):371‐84.doi:10.1038/ng.2566. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology 2012;13(11):1141-1151. Couch F, Gaudet M, Antoniou A, Ramus S, Kuchenbaecker K, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova O, Andrulis I, for OCGN, Ozcelik H, Mulligan A, Thomassen M, Gerdes A, Jensen U, Skytte A, Kruse T, Caligo M, von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona H, Karlsson P, for SWE, Nathanson K, Rebbeck T, Domchek S, Jakubowska A, Lubinski J, Jaworska K, Durda K, Z+éowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, G+¦rski B, Osorio A, Dur+ín M, Tejada M, Benitez J, Hamann U, Hogervorst F, for HEBO, van Os T, van Leeuwen FE, Meijers-Heijboer H, Wijnen J, Blok M, Kets M, Hooning M, Oldenburg R, Ausems M, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson S, Morrison P, Walker L, Porteous M, Kennedy MJ, Side L, for EMBR, Bove B, Godwin A, Stoppa-Lyonnet D, for GEMO, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, L. Boutry-Kryza N, Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch H, Snyder C, Buys S, Daly M, Terry M, Chung W, John E, Miron A, Southey M, Hopper J, Goldgar D, Singer C, Rappaport C, Tea M, Fink-Retter A, Hansen T, Nielsen F, Arason A+, Vijai J, Shah S, Sarrel K, Robson M, Piedmonte M, Phillips K, Basil J, Rubinstein W, Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther S, Pharoah P, Odunsi K, Karlan B, Walsh C, Olah E, Teo S, Ganz P, Beattie M, van Rensburg E, Dorfling C, Diez O, Kwong A, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen T, Nevanlinna H, Tischkowitz M, Spurdle A, Neuhausen S, Ding Y, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel A, Giannini G, Varesco L, Radice P, Greene M, Mai P, Easton D, Chenevix-Trench G, for kConFab investigators, Offit K, Simard J, on behalf of the Consortium of Investigators of Modifiers of BRCA. Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention 2012 Apr; 21(4):645-657. Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, 't Veer LJ, Udo R, Dunning AM, Greco D, Aittomaki K, Blomqvist C, Shah M, Nordestgaard BG, Flyger H, Hopper JL, Southey MC, Apicella C, Garcia-Closas M, Sherman M, Lissowska J, Seynaeve C, Huijts PE, Tollenaar RA, Ziogas A, Ekici AB, Rauh C, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Andrulis I, Ozcelik H, Mulligan AM, Glendon G, Hall P, Czene K, Liu J, Chang-Claude J, Wang-Gohrke S, Eilber U, Nickels S, Dork T, Schiekel M, Bremer M, Park-Simon TW, Giles GG, Severi G, Baglietto L, Hooning MJ, Martens JW, Jager A, Kriege M, Lindblom A, Margolin S, Couch FJ, Stevens KN, Olsen JE, Kosel M, Cross SS, Balasubramanian SP, Reed MW, Miron A, John E, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Kauppila S, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Chenevix-Trench G, Lambrechts D, Dieudonne AS, Hatse S, van Limbergen E, Benitez J, Milne RL, Zamora MP, Arias Perez JI, Bonanni B, Peissel B, Loris B, Peterlongo P, Rajaraman P, Schonfeld SJ, Anton-Culver H, Devilee P, Beckmann MW, Slamon DJ, Phillips KA, Figueroa JD, Humphreys MK, Easton DF, Schmidt MK. The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet 2012 Sep 1; 21(17):3926-39. Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, Gauthier-Villars M, Lasset C, Fricker JP, Peock S, Frost D, Evans DG, Eeles RA, Paterson J, Manders P, van Asperen CJ, Ausems

MG, Meijers-Heijboer H, Thierry-Chef I, Hauptmann M, Goldgar D, Rookus MA, van Leeuwen FE; GENEPSO; EMBRACE; HEBON. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 2012; 345:e5660. Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Gronwald J, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Osorio A, Benitez J, Duran M, Tejada MI, Hamann U, Rookus M, van Leeuwen FE, Aalfs CM, Meijers-Heijboer HE, van Asperen CJ, van Roozendaal KE, Hoogerbrugge N, Margriet Collee J, Kriege M, van der Luijt RB, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Pathak H, Godwin AK, Stoppa-Lyonnet D, Caux-Moncoutier V, de Pauw A, Gauthier-Villars M, Mazoyer S, Leone M, Calender A, Lasset C, Bonadona V, Hardouin A, Berthet P, Bignon YJ, Uhrhammer N, Faivre L, Loustalot C, Buys S, Daly M, Miron A, Beth Terry M, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea Maria MK, Pfeiler G, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Kirchhoff T, Gaudet MM, Vijai J, Robson M, Piedmonte M, Phillips KA, Van Le L, Hoffman JS, Toland AE, Montagna M, Tognazzo S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Tornero E, Navarro M, Moysich KB, Karlan BY, Gross J, Olah E, Vaszko T, Teo SH, Ganz PA, Beattie MS, Dorfling CM, van Rensburg EJ, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schafer D, Caldes T, de la Hoya M, Nevanlinna H, Aittomaki K, Plante M, Spurdle AB, Neuhausen SL, Ding YC, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H, Pharoah PD, Gayther SA, Simard J, Easton DF, Couch FJ, Chenevix-Trench G. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat 2012 Apr; 33(4):690-702. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benitez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schonbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Canadas C, Heikkinen T, Heikkila P, Aittomaki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21(1):134-147 Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Putignano AL, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Cruger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Cajal T, Fostira F, Andres R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gomez Garcia EB, Peock S, Cook M, Frost D, Platte R, Leyland J, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, Kennedy MJ, Miedzybrodzka Z, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M,

Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frenay M, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D, Singer CF, Tea MK, Pfeiler G, Dressler AC, Hansen TO, Jonson L, Ejlertsen B, Barkardottir RB, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Toland AE, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schonbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomaki K, Dumont M, Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB, Neuhausen SL, Chun Ding Y, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2011; 20(16):3304-3321. Cox DG, Simard J, Sinnett D, Hamdi Y, Soucy P, Ouimet M, Barjhoux L, Verny-Pierre C, McGuffog L, Healey S, Szabo C, Greene MH, Mai PL, Andrulis IL, Thomassen M, Gerdes AM, Caligo MA, Friedman E, Laitman Y, Kaufman B, Paluch SS, Borg A, Karlsson P, Askmalm MS, Bustinza GB, Nathanson KL, Domchek SM, Rebbeck TR, Benitez J, Hamann U, Rookus MA, van den Ouweland AM, Ausems MG, Aalfs CM, van Asperen CJ, Devilee P, Gille HJ, Peock S, Frost D, Evans DG, Eeles R, Izatt L, Adlard J, Paterson J, Eason J, Godwin AK, Remon MA, Moncoutier V, Gauthier-Villars M, Lasset C, Giraud S, Hardouin A, Berthet P, Sobol H, Eisinger F, Bressac de Paillerets B, Caron O, Delnatte C, Goldgar D, Miron A, Ozcelik H, Buys S, Southey MC, Terry MB, Singer CF, Dressler AC, Tea MK, Hansen TV, Johannsson O, Piedmonte M, Rodriguez GC, Basil JB, Blank S, Toland AE, Montagna M, Isaacs C, Blanco I, Gayther SA, Moysich KB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Sutter C, Gadzicki D, Fiebig B, Caldes T, Laframboise R, Nevanlinna H, Chen X, Beesley J, Spurdle AB, Neuhausen SL, Ding YC, Couch FJ, Wang X, Peterlongo P, Manoukian S, Bernard L, Radice P, Easton DF, Chenevix-Trench G, Antoniou AC, Stoppa-Lyonnet D, Mazoyer S, Sinilnikova OM. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet 2011; 20(23):4732-4747 Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retel VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat 2011; 130(3):725-734. Im KM, Kirchhoff T, Wang X, Green T, Chow CY, Vijai J, Korn J, Gaudet MM, Fredericksen Z, Shane Pankratz V, Guiducci C, Crenshaw A, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Mai PL, Greene MH, Piedmonte M, Rubinstein WS, Hogervorst FB, Rookus MA, Collee JM, Hoogerbrugge N, van Asperen CJ, Meijers-Heijboer HE, van Roozendaal CE, Caldes T, Perez-Segura P, Jakubowska A, Lubinski J, Huzarski T, Blecharz P, Nevanlinna H, Aittomaki K, Lazaro C, Blanco I, Barkardottir RB, Montagna M, D'Andrea E, Devilee P, Olopade OI, Neuhausen SL, Peissel B, Bonanni B, Peterlongo P, Singer CF, Rennert G, Lejbkowicz F, Andrulis IL, Glendon G, Ozcelik H, Toland AE, Caligo MA, Beattie MS, Chan S, Domchek SM, Nathanson KL, Rebbeck TR, Phelan C, Narod S, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Hansen TV, Osorio A, Benitez J, Duran M, Weitzel JN, Garber J, Hamann U, Peock S, Cook M, Oliver CT, Frost D, Platte R, Evans DG, Eeles R, Izatt L, Paterson J, Brewer C, Hodgson S, Morrison PJ, Porteous M, Walker L, Rogers MT, Side LE, Godwin AK, Schmutzler RK, Wappenschmidt B, Laitman Y, Meindl A, Deissler H, Varon-Mateeva R, Preisler-Adams S, Kast K, Venat-Bouvet L, Stoppa-Lyonnet D, Chenevix-Trench G, Easton DF, Klein RJ, Daly MJ, Friedman E, Dean M, Clark AG, Altshuler DM, Antoniou AC, Couch FJ, Offit K, Gold B. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet 2011; 130(5):685-699. Manders P, Pijpe A, Hooning MJ, Kluijt I, Vasen HF, Hoogerbrugge N, van Asperen CJ, Meijers-Heijboer H, Ausems MG, van Os TA, Gomez-Garcia EB, Brohet RM, van Leeuwen FE, Rookus MA. Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat 2011; 126(1):193-202 Mook S, van ‘t Veer L, Rutgers E, Ravdin P, van de Velde A, van Leeuwen FE, Visser O, Schmidt M. Independent Prognostic Value of Screen Detection in Invasive Breast Cancer. J Nat Cancer Inst 2011; 103(7):585-597 Osorio A, Milne RL, Alonso R, Pita G, Peterlongo P, Teule A, Nathanson KL, Domchek SM, Rebbeck T, Lasa A, Konstantopoulou I, Hogervorst FB, Verhoef S, van Dooren MF, Jager A, Ausems MGEM,

Aalfs CM, van Asperen CJ, Vreeswijk M, Waisfisz Q, van Roozendaal CE, Ligtenberg MJ, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Curzon B, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Adlard J, Eccles D, Ong K, Douglas F, Downing S, Brewer C, Walker L, Nevanlinna H, Aittomaki K, Couch FJ, Fredericksen Z, Lindor NM, Godwin A, Isaacs C, Caligo MA, Loman N, Jernstrom H, Barbany-Bustinza G, Liljegren A, Ehrencrona H, Stenmark-Askmalm M, Feliubadalo L, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Fortuzzi S, Johannsson OT, Chenevix-Trench G, Chen XC, Beesley J, Spurdle AB, Sinilnikova OM, Healey S, McGuffog L, Antoniou AC, Brunet J, Radice P, Benitez J. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. Br J Cancer 2011; 104(8):1356-1361 Ramus S, Kartsonaki C, Gayther S, Pharoah P, Sinilnikova O, Beesley J, Chen X, McGuffog L, Healey S, Couch F, Wang X, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene M, Mai P, Andrulis I, Glendon G, Ozcelik H, OCGN, Thomassen M, Gerdes A, Kruse T, Cruger D, Jensen U, Caligo M, Olsson H+, Kristoffersson U, Lindblom A, Arver B, Karlsson P, Stenmark Askmalm M, Borg A, Neuhausen S, Ding Y, Nathanson K, Domchek S, Jakubowska A, Lubiäski J, Huzarski T, Byrski T, Gronwald J, G+¦rski B, Cybulski C, DÖbniak T, Osorio A, Durín M, Tejada M, Ben¡tez J, Hamann U, Rookus M, Verhoef S, Tilanus-Linthorst M, Vreeswijk M, Bodmer D, Ausems M, van Os T, Asperen C, Blok M, Meijers-Heijboer H, HEBON, EMBRACE, Peock S, Cook M, Oliver C, Frost D, Dunning A, Evans DG, Eeles R, Pichert G, Cole T, Hodgson S, Brewer C, Morrison P, Porteous M, Kennedy MJ, Rogers M, Side L, Donaldson A, Gregory H, Godwin A, Stoppa-Lyonnet D, Moncoutier V, Castera L, Mazoyer S, Barjhoux L, Bonadona V, Leroux D, Faivre L, Lidereau R, Nogues C, Bignon Y, Prieur F, Collonge-Rame M, Venat-Bouvet L, Fert-Ferrer S, Study Collaborators GEMO, Miron A, Buys S, Hopper J, Daly M, John E, Terry M, Goldgar D, BCFR, Hansen T, Jhonson L, Ejlertsen B, Agnarsson B, Offit K, Kirchhoff T, Vijai J, Dutra-Clarke A, Przybylo J, Montagna M, Casella C, Imyanitov E, Janavicius R, Blanco I, Lízaro C, Moysich K, Karlan B, Gross J, Beattie M, Schmutzler R, Wappenschmidt B, Meindl A, Ruehl I, Fiebig B, Sutter C, Arnold N, Deissler H, Varon-Mateeva R, Kast K, Niederacher D, Gadzicki D, Caldes T, de la Hoya M, Nevanlinna H, Aittomñki K, Simard J, Soucy P, kConFab I, Spurdle A, Holland H, Chenevix-Trench G, Easton D, Antoniou A, on behalf of Consortium of Investigators of Modifiers of BRCA. Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. J Nat Cancer Inst 2011; 103(2):105-116. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomäki K, Heikkilä P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van 't Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O'Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dörk T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Pérez JI, Menéndez Rodríguez P, Zamora P, Benítez J, Ko YD, Fischer HP, Hamann U, Pesch B, Brüning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubiński J, Huzarski T, Byrski T, Górski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collée M, Wang-Gohrke S, Pylkäs K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Ørsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. J Nat Cancer Inst 2011; 103(3):250-263. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH,

Rennert G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL; Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B; SWE-BRCA, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M; HEBON, Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S; EMBRACE, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L; GEMO, Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frénay M, Vénat-Bouvet L; GEMO, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TV, Jønson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X; kConFab, Platte R, Chenevix-Trench G, Easton DF; CIMBA. Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research 2010; 70(23):9742-9754.

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010; 7(5):e1000279 Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C, McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladieff L, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-Trench G, Spurdle AB, Chen X, Beesley J, Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A, van der Luijt RB, van Os TA, van Leeuwen FE, Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Cajal T, Konstantopoulou I, Benitez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna H, Aittomaki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, Godwin AK, Hamann U, Schmutzler RK. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010; 19(11):2859-2868 Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, Heikkinen T, Aittomaki K, Blomqvist C, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schurmann P, Waltes R, Bremer M, Dork T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Humphreys K, Liu J, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G, Beesley J, Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Ko YD, Hamann U, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Milne RL, Benitez J, Arias JI, Pita G, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, Garcia-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang-Gohrke S, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Margolin S, Lindblom A, Humphreys MK, Morrison J, Platte R, Easton DF, Peto J. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev 2010; 19(9):2143-2151. Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segre AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, Study Collaborators GEMO, Hogervorst FB, Rookus MA, Collee JM, Hoogerbrugge N, van Roozendaal KE, Piedmonte M, Rubinstein W, Nerenstone S, Van Le L, Blank

SV, Caldes T, de la Hoya M, Nevanlinna H, Aittomaki K, Lazaro C, Blanco I, Arason A, Johannsson OT, Barkardottir RB, Devilee P, Olopade OI, Neuhausen SL, Wang X, Fredericksen ZS, Peterlongo P, Manoukian S, Barile M, Viel A, Radice P, Phelan CM, Narod S, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H, Toland AE, Montagna M, D'Andrea E, Friedman E, Laitman Y, Borg A, Beattie M, Ramus SJ, Domchek SM, Nathanson KL, Rebbeck T, Spurdle AB, Chen X, Holland H, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Overeem Hansen TV, Nielsen FC, Greene MI, Mai PL, Osorio A, Duran M, Andres R, Benitez J, Weitzel JN, Garber J, Hamann U, Peock S, Cook M, Oliver C, Frost D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Walker L, Eason J, Barwell J, Godwin AK, Schmutzler RK, Wappenschmidt B, Engert S, Arnold N, Gadzicki D, Dean M, Gold B, Klein RJ, Couch FJ, Chenevix-Trench G, Easton DF, Daly MJ, Antoniou AC, Altshuler DM, Offit K, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, Sinilnikova O, Barjhoux L, Giraud S, Leone M, Mazoyer S, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C, Moncoutier V, Belotti M, de Pauw A, Bressac-de-Paillerets B, Remenieras A, Byrde V, Caron O, Lenoir G, Bignon YJ, Uhrhammer N, Lasset C, Bonadona V, Hardouin A, Berthet P, Sobol H, Bourdon V, Noguchi T, Eisinger F, Coulet F, Colas C, Soubrier F, Coupier I, Peyrat JP, Fournier J, Revillion F, Vennin P, Adenis C, Rouleau E, Lidereau R, Demange L, Nogues C, Muller D, Fricker JP, Longy M, Sevenet N, Toulas C, Guimbaud R, Gladieff L, Feillel V, Leroux D, Dreyfus H, Rebischung C, Cassini C, Faivre L, Prieur F, Ferrer SF, Frenay M, Venat-Bouvet L, Lynch HT, Hogervorst FB, Rookus MA, Collee JM, Hoogerbrugge N, van Roozendaal KE, Hogervorst FB, Verhoef S, Verheus M, 't Veer LJ, van Leeuwen FE, Rookus MA, Collee M, van den Ouweland AM, Jager A, Hooning MJ, Tilanus-Linthorst MM, Seynaeve C, van Asperen CJ, Wijnen JT, Vreeswijk MP, Tollenaar RA, Devilee P, Ligtenberg MJ, Hoogerbrugge N, Ausems MG, van der Luijt RB, Aalfs CM, van Os TA, Gille JJ, Waisfisz Q, Meijers-Heijboer H, Gomez-Garcia EB, van Roozendaal CE, Blok MJ, Oosterwijk JC, van der Hout AH, Mourits MJ, Vasen HF, Spurdle AB, Chenevix-Trench G. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 2010; 6(10):e1001183 Pijpe A, Manders P, Brohet RM, Collee JM, Verhoef S, Vasen HF, Hoogerbrugge N, van Asperen CJ, Dommering C, Ausems MG, Aalfs CM, Gomez-Garcia EB, Van’t Veer LJ, van Leeuwen FE, Rookus MA. Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Br Can Res Treat 2010; 120(1): 235-44 Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H; OCGN, Thomassen M, Gerdes AM, Kruse TA, Cruger D, Jensen UB, Caligo MA, Olsson H, Kristoffersson U, Lindblom A, Arver B, Karlsson P, Stenmark Askmalm M, Borg A, Neuhausen SL, Ding YC, Nathanson KL, Domchek SM, Jakubowska A, Lubiński J, Huzarski T, Byrski T, Gronwald J, Górski B, Cybulski C, Dębniak T, Osorio A, Durán M, Tejada MI, Benítez J, Hamann U, Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Bodmer D, Ausems MG, van Os TA, Asperen CJ, Blok MJ, Meijers-Heijboer HE; HEBON; EMBRACE, Peock S, Cook M, Oliver C, Frost D, Dunning AM, Evans DG, Eeles R, Pichert G, Cole T, Hodgson S, Brewer C, Morrison PJ, Porteous M, Kennedy MJ, Rogers MT, Side LE, Donaldson A, Gregory H, Godwin A, Stoppa-Lyonnet D, Moncoutier V, Castera L, Mazoyer S, Barjhoux L, Bonadona V, Leroux D, Faivre L, Lidereau R, Nogues C, Bignon YJ, Prieur F, Collonge-Rame MA, Venat-Bouvet L, Fert-Ferrer S; GEMO Study Collaborators, Miron A, Buys SS, Hopper JL, Daly MB, John EM, Terry MB, Goldgar D; BCFR, Hansen TO, Jønson L, Ejlertsen B, Agnarsson BA, Offit K, Kirchhoff T, Vijai J, Dutra-Clarke AV, Przybylo JA, Montagna M, Casella C, Imyanitov EN, Janavicius R, Blanco I, Lázaro C, Moysich KB, Karlan BY, Gross J, Beattie MS, Schmutzler R, Wappenschmidt B, Meindl A, Ruehl I, Fiebig B, Sutter C, Arnold N, Deissler H, Varon-Mateeva R, Kast K, Niederacher D, Gadzicki D, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Simard J, Soucy P; kConFab Investigators, Spurdle AB, Holland H, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2. Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. J Nat Cancer Inst 2011; 103(2):105-116 Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomäki K, Heikkilä P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van 't Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O'Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R,

Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dörk T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Pérez JI, Menéndez Rodríguez P, Zamora P, Benítez J, Ko YD, Fischer HP, Hamann U, Pesch B, Brüning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubiński J, Huzarski T, Byrski T, Górski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collée M, Wang-Gohrke S, Pylkäs K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Ørsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M. Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. J Nat Cancer Inst 2011; 103(3):250-263 Verloop J, van Leeuwen FE, Helmerhorst TJ, van Boven HH, Rookus MA. Cancer risk in DES daughters. Cancer Causes Control 2010; 21(7):999-1007 Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, Cook M, Evans DG, Eeles R; EMBRACE, Nogues C, Faivre L, Gesta P; GENEPSO, van Leeuwen FE, Ausems MG, Osorio A; GEO-HEBON, Caldes T, Simard J, Lubinski J, Gerdes AM, Olah E, Fürhauser C, Olsson H, Arver B, Radice P, Easton DF, Goldgar DE. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epid Bio Prev 2009; 18(2) 601. Gaudet MM, Milne RL, Cox A, Camp NJ, Goode EL, Humphreys MK, Dunning AM, Morrison J, Giles GG, Severi G, Baglietto L, English DR, Couch FJ, Olson JE, Wang X, Chang-Claude J, Flesch-Janys D, Abbas S, Slazar R, Mannermaa A, Kataja V, Kosma VM, Lindblom A, Margolin S, Heikkinen T, Kämpjärvi K, Aaltonen K, Nevanlinna H, Bogdanova N, Coinac I, Schürmann P, Dörk T, Bartram CR, Schmutzler RK, Tchatchou S, Burwinkel B, Brauch H, Torres D, Hamann U, Justenhoven C, Ribas G, Arias JI, Benitez J, Bojesen SE, Nordestgaard BG, Flyger HL, Peto J, Fletcher O, Johnson N, Dos Santos Silva I, Fasching PA, Beckmann MW, Strick R, Ekici AB, Broeks A, Schmidt MK, Van Leeuwen FE, Van ’t Veer LJ, Southey MC, Hopper JL, Apicella C, McCredie MRE, Haiman CA, Henderson BE, Le March L, Kolonel LN, Kristensen V, Grenaker Alnæs G, Hunter DJ, Kraft P, Cox DG, Hankinson SE, Seynaeve C, Vreeswijk MPG, Tollenaar RAEM, Devilee P, Chanock S, Lissowska J, Brinton L, Peplonska B, Czene K, Hall P, Li Y, Liu J, Balasubramanian S, Rafii S, Reed MWR, Pooley KA, Conroy D, Baynes C, Kang D, Yoo KY, Noh DY, Ahn SE, Shen CY, Wang HC, Yu JC, WU PE, Anton-Culver H, Ziogoas A, Egan K, Newcomb P, Titus-Ernstoff L, Trentham Dietz E, Sigurdson AJ, Alexander BH, Bhatti P, Allen-Brady K, Cannon-Albright LA, Wong J, AOCS Study Group, Chenevix-Trench G, Spurdle AB, Beesley J, Pharoah PDP, Easton DF, and Garcia-Closas M

on behalf of the Breast Cancer Association Consortium. Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium. Cancer Epi Biom prev. 2009; 18(5); 1610-6. PMID 19423537 Schmidt MK, Tommiska J, Broeks A, Van Leeuwen FE, Van ‘t Veer LJ, Pharaoah PDP, Easton DF, Shah M, Humphreys M, Dörk T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression in survival of breast cancer patients. Br Can Res. 2009; 11(6):R89. Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van ’t Veer LJ, Pharoa PDP, Easton DF, Shah M, Humphreys M. Interaction of p53 expression and single nucleotide polymorphisms TP53 R72P and MDM2 SNP309 in survival of breast cancer patients. Breast Cancer Res Dec 2009; 11(6):R89 Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op de Beeck L, Faes C, Bruckers L, Mertens R, Coebergh JW, van Leeuwen FE, Buntinx F.

Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat. 2009 Nov;118 (2):425-432 Gronwald J, Pijpe A, Byrski T, Huzarski T, Stawicka M, Cybulski C, van Leeuwen FE, Lubínski J, Narod SA. Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Res Treat 2008; 112(3):581 Voskuil DW, Vrieling A, Korse CM, Beijnen JH, Bonfrer JM, van Doorn J, Kaas R, Oldenburg HS, Russell NS, Rutgers EJ, Verhoef S, van Leeuwen FE, van't Veer LJ, Rookus MA. Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. Nutr Cancer 2008; 60:342 – 353. Vrieling A, Rookus MA, Kampman E, Bonfrer JMG, Bosma A, Cats A, van Doorn J, Korse CM, Witteman BJM, van Leeuwen FE, van ʼt Veer LJ, Voskuil DW. No effect of red clover-derived isoflavone intervention on the Insulin-like Growth Factor (IGF) system; a randomized cross-over trial in women. Cancer Epidemiol Biomarkers Prev. Oct. 2008; 17(10): 2585-2593. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, Peock S, Eeles RA, Cook M, Chu C, Noguès C, Lasset C, Berthet P, Meijers-Heijboer H, Gerdes AM, Olsson H, Caldes T, van Leeuwen FE, Rookus MA. Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007; 25:3831-3836. Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S, Davidson R, Izatt L, Cole T, Nogues C, Luporsi E, Huiart L, Hoogerbrugge N, van Leeuwen FE, Osorio A, Eyfjord J, Radice P, Goldgar DE, Easton DF; Epidemiological Study of Familial Breast Cancer (EMBRACE); Gene Etude Prospective Sein Ovaire (GENEPSO); Genen Omgeving studie van de werkgroep Hereditiair Borstkanker Onderzoek Nederland (GEO-HEBON); International BRCA1/2 Carrier Cohort Study (IBCCS) collaborators group. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2007; 16(4):740-746. Monninkhof EM, Elias SG, Vlems FA, van der Tweel I, Schuit J, Voskuil DW, van Leeuwen FE. Physical activity and breast cancer: a systematic review. Epidemiol 2007; 18(1):137-157. Schmidt MK, Tollenaar RAEM, de Kemp SR, Broeks A, Cornelisse CJ, Smit VTHBM, Peterse JL, van Leeuwen FE, van 't Veer LJ. Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation. J Clin Oncol 2007; 25(1):64-69. Soerjomataram I, Coebergh J, Louwman M, Visser O, van Leeuwen F. Does the Decrease in Hormone Replacement Therapy Also Affect Breast Cancer Risk in the Netherlands? J Clin Oncol 2007; 25(31):5038-5039 Voskuil DW, Monninkhof EM, Elias SG, Vlems FA, van Leeuwen FE, and the Task Force Physical Activity and Cancer. Physical activity and endometrial cancer risk, a systematic review of current evidence. Cancer Epidemiol Biomarkers Prev 2007; 16(4):639-648. Vrieling A, Voskuil DW, Bonfrer JM, Korse CM, van Doorn J, Cats A, Depla AC, Timmer R, Witteman BJ, van Leeuwen FE, Van't Veer LJ, Rookus MA, Kampman E. Lycopene supplementation elevates circulating insulin-like growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer. Am J Clin Nutr. 2007; 86(5): 1456-1462. Andrieu N, Goldgar DE, Easton DF, Rookus MA, Brohet R, Cardis E, Antoniou AC, Peock S, Evans G,

Eccles D, Douglas F, EMBRACE, Nogues C, Gauthier-Villars M, Chompret A, GENEPSO, van Leeuwen FE, Kluijt I, GEO-HEBON, Benitez J, Arver B, Olah E, the IBCCS collaborators group, Chang-Claude J. Pregnancies, breastfeeding and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 2006; 98:535-544. Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker J-P, Nogues C, van ’t Veer LJ, van Leeuwen FE and Goldgar D. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study; A report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol 2006; 24(21):3361-3366. Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, van 't Veer LJ, Rookus MA, van Leeuwen FE; Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42(9):711-719. Collaborative Group on Hormonal Factors in Breast Cancer (van Leeuwen FE, Member of Steering Group). Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet 2004; 363(9414):1007-1016. Rookus MA, van Leeuwen FE. Effects of estrogen-only treatment in postmenopausal women. JAMA 2004;292(6):683-686. Visser O, van der Kooy K, van Peppen AM, Öry FG, van Leeuwen FE. Breast cancer risk among first-generation migrants in the Netherlands. Br J Cancer 2004; 90(11):2135-2137. Van Leeuwen FE, Rookus MA. Breast cancer and hormone-replacement therapy: the Million Women Study. Lancet 2003; 362(9392):1330-1331. VandenBroucke JP, Van Leeuwen FE, Helmerhorst FM. [Breast cancer and the use of the hormones around the menopause]. Ned Tijdschr Geneeskd 2003; 147(38):1829-1834. Rookus MA, Brohet R, van Leeuwen FE. Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2003; 95(13):1012. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Jr., Coates RJ, Liff JM, Talamini R, Chantarakul N, Koetsawang S, Rachawat D, Morabia A, Schuman L, Stewart W, Szklo M, Bain C, Schofield F, Siskind V, Band P, Coldman AJ, Gallagher RP, Hislop TG, Yang P, Kolonel LM, Nomura AM, Hu J, Johnson KC, Mao Y, De Sanjose S, Lee N, Marchbanks P, Ory HW, Peterson HB, Wilson HG, Wingo PA, Ebeling K, Kunde D, Nishan P, Hopper JL, Colditz G, Gajalanski V, Martin N, Pardthaisong T, Silpisornkosol S, Theetranont C, Boosiri B, Chutivongse S, Jimakorn P, Virutamasen P, Wongsrichanalai C, Ewertz M, Adami HO, Bergkvist L, Magnusson C, Persson I, Chang-Claude J, Paul C, Skegg DC, Spears GF, Boyle P, Evstifeeva T, Daling JR, Hutchinson WB, Malone K, Noonan EA, Stanford JL, Thomas DB, Weiss NS, White E, Andrieu N, Bremond A, Clavel F, Gairard B, Lansac J, Piana L, Renaud R, Izquierdo A, Viladiu P, Cuevas HR, Ontiveros P, Palet A, Salazar SB, Aristizabel N, Cuadros A, Tryggvadottir L, Tulinius H, Bachelot A, Le MG, Peto J, Franceschi S, Lubin F, Modan B, Ron E, Wax Y, Friedman GD, Hiatt RA, Levi F, Bishop T, Kosmelj K, Primic-Zakelj M, Ravnihar B, Stare J, Beeson WL, Fraser G, Bullbrook RD, Cuzick J, Duffy SW, Fentiman IS, Hayward JL, Wang DY, McMichael AJ, McPherson K, Hanson RL, Leske MC, Mahoney MC, Nasca PC, Varma AO, Weinstein AL, Moller TR, Olsson H, Ranstam J, Goldbohm RA, van den Brandt PA, Apelo RA, Baens J, de la Cruz JR, Javier B, Lacaya LB, Ngelangel CA, La Vecchia C, Negri E, Marubini E, Ferraroni M, Gerber M, Richardson S, Segala C, Gatei D, Kenya P, Kungu A, Mati JG, Brinton LA, Hoover R, Schairer C, Spirtas

R, Lee HP, Rookus MA, van Leeuwen FE, Schoenberg JA, McCredie M, Gammon MD, Clarke EA, Jones L, Neil A, Vessey M, Yeates D, Appleby P, Banks E, Beral V, Bull D, Crossley B, Goodill A, Green J, Hermon C, Key T, Langston N, Lewis C, Reeves G, Collins R, Doll R, Peto R, Mabuchi K, Preston D, Hannaford P, Kay C, Rosero-Bixby L, Gao YT, Jin F, Yuan JM, Wei HY, Yun T, Zhiheng C, Berry G, Cooper Booth J, Jelihovsky T, MacLennan R, Shearman R, Wang QS, Baines CJ, Miller AB, Wall C, Lund E, Stalsberg H, Shu XO, Zheng W, Katsouyanni K, Trichopoulou A, Trichopoulos D, Dabancens A, Martinez L, Molina R, Salas O, Alexander FE, Anderson K, Folsom AR, Hulka BS, Bernstein L, Enger S, Haile RW, Paganini-Hill A, Pike MC, Ross RK, Ursin G, Yu MC, Longnecker MP, Newcomb P, Bergkvist L, Kalache A, Farley TM, Holck S, Meirik O. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. Br J Cancer 2002; 87(11):1234-1245. Collaborative Group on Hormonal Factors in Breast Cancer (van Leeuwen FE, Member of Steering Group). Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360(9328):187-195. Collaborative Group on Hormonal Factors in Breast Cancer (van Leeuwen FE, Member of Steering Group). Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002; 87(11):1234-1245. Bergman L, Beelen MLR, Gallee MPW, Hollema H, Benraadt J, Van Leeuwen FE. [reply]. Risk and prognosis of endometrial cancer following tamoxifen for breast cancer. Lancet 2001;357: 65-67. Collaborative Group on Hormonal Factors in Breast Cancer (van Leeuwen FE, Member of Steering Group). Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358(9291):1389-1399. Verloop J, Rookus MA, van Leeuwen FE. Prevalence of gynecological cancer in women exposed to diethylstilbestrol. N Engl J Med 2000;342: 1838-1839. Verloop J, Rookus MA, Van der Kooy K, van Leeuwen FE. Physical activity and breast cancer risk in women aged 20-54 years. J Natl Cancer Inst 2000; 92:128-135. Burger CW, van Leeuwen FE, Scheele F, Kenemans P. Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 1999; 32: 69-76. Van der Kooy K, Rookus MA, Peterse HL, van Leeuwen FE [reply]. P53 protein overexpression in relation to risk factors for breast cancer. Am J Epidemiol 1998; 147:511-512. Rookus Ma, van Leeuwen FE, Hamerlynck JV. [Last word on hormon ereplacement and breast cancer?]. Ned Tijdschr Geneeskd 1998; 142(3):111-113. Van Leeuwen F, Bergman L, Benraadt J. Does risk of endometrial cancer increase with longer duration of tamoxifen use? Eur J Cancer 34 Suppl 1998; 4:S44-S45. Burger CW, Koomen I, Peters NAJB, van Leeuwen FE, Kenemans P.

Postmenopausal hormone replacement therapy and cancer of the female genital tract and the breast. Eur Menopause J 1997; 4:23-36. Collaborative Group on Hormonal Factors in Breast Cancer (van Leeuwen FE, Member of Steering Group) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350:1047-1059. Rookus MA, van Leeuwen FE Re: Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case-control study [reply]. J Natl Cancer Inst 1997; 89:589-590. Burger CW, Koomen I, Peters NAJB, van Leeuwen FE, Kenemans P. HRT and cancer of the female genital tract and the breast. G ynecol Forum 1996; 1: 22-29. Rookus MA, van Leeuwen FE. Induced abortion and risk for breast cancer: reporting (recall) bias in a Dutch case-control study. J Natl Cancer Inst 1996; 88:1759-1764. Van der Kooy K, Rookus MA, Peterse HL, van Leeuwen FE. P53 protein overexpression in relation to risk factors for breast cancer. Am J Epidemiol 1996; 144: 924-933. Hamerlynck HV, van Leeuwen FE,. [Long-term postmenopausal hormone substitution and incidence of breast cancer: The Nurses’Health Study]. Ned Tijdschr Geneeskd 1996; 140(14):759-761. Collaborative Group on Hormonal Factors in Breast Cancer (van Leeuwen FE, Member of Steering Group). Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 329 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347:1713-27. Collaborative Group on Hormonal Factors in Breast Cancer (van Leeuwen FE, Member of Steering Group). Breast cancer and hormonal contraceptives: further results. Contraception 1996; 54:1S-106S. Van Leeuwen FE, Kenemans P. HRT and the risk of breast cancer. Eur Menopause J 1995; 2:13-15. Rookus MA, van Leeuwen FE. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Lancet 1994; 344:844-851. Jansen DF, Van Barneveld TA, van Leeuwen FE. [A causal connection between luncg cancer and passive smoking: the report from the American Environmental Protection Agency]. Ned Tijdschr Geneeskd 1994; 138:500-503. Vasen HFA, Beex LVAM, Cleton FJ, Collette HJA, Van Dongen JA, van Leeuwen FE, Crommelin MA, Meera Khan P. Clinical heterogeneity of hereditary breast cancer and its impact on screening protocols: the Dutch experience on 24 families under surveillance. Eur J Cancer 1993; 29A:1111-1114. Treurniet HF, Rookus MA, Peterse HL, Hart AAM, van Leeuwen FE. Differences in breast cancer risk factors according to neu (c-erb-2) protein overexpression of the breast tumor.

Cancer Res 1992; 52:2344-2345. Haring MH, Rookus MA, van Leeuwen FE. [Does breast feeding protect against braest cancer? An epidemiological study]. Ned Tijdschr Geneeskd 1992; 136:743-747. Van Leeuwen FE, Van Duijn CM, Camps MHTH, Kempers BAM, Mentjens MFMH, Mulder HB, Schoutens EG, Zwijsen RML, Rookus MA. Agreement between oral contraceptive users and prescribers: implications for case-control studies. Contraception 1991; 45:399-408. Van Leeuwen FE. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer. Acta Endocrinologica 1991; 123:suppl. 1, 13-26. Van Leeuwen FE. [Breast carcinoma and the pill: a puzzle with missing pieces]. Ned Tijdschr Geneeskd 1989;133(46):2300-2303. Van Leeuwen FE, Rookus MA. The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer. Eur J Cancer Clin Oncol 1989; 15:1961-1972. Van Leeuwen FE, Verbeek AL, Coebergh JW. [Breast carcinoma and oral contraceptives: the disadvantage of doubt]. Ned Tijdschr Geneeskd 1987; 131(45):2012-016.

III Adverse effects of ovarian stimulation for IVF in women and IVF-conceived offspring

M Spaan, AW van den Belt-Dusebout, MM van den Heuvel-Eibrink, M Hauptmann, CB Lambalk, CW Burger, FE van Leeuwen, on behalf of the OMEGA-steering group. Risk of cancer in children and young adults conceived by assisted reproductive technology. Human Reproduction.In Press. Derks-Smeets IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, van Golde RJT, Smits LJ, Caanen B, van Asperen CJ, Ausems M, Collee M, van Engelen K, Kets CM, van der Kolk L, Oosterwijk JC, van Os TAM, Rookus MA, van Leeuwen FE, Gomez Garcia EB. Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers. Br J Cancer. 2018;doi: 10.1038/s41416-018-0139-1. Honorato T, Hoek A, Henningsen AK, Pinborg A, Lidegaard O, Mooij T, van Leeuwen FE, Land J, Groen H, Haadsma M. Low oocyte yield during IVF treatment and the risk of a trisomic pregnancy. Reproductive biomedicine online. 2017;35(6):685.  Van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JS, van Santbrink EJ, van der Westerlaken LA, Cohlen BJ, Braat DD, Smeenk JM, Land JA, Goddijn M, van Golde RJ, van Rumste MM, Schats R, Józwiak K, Hauptmann M, Rookus MA, Burger CW, van Leeuwen FE. Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA. 2016;316(3):300 Gameiro S, van den Belt-Dusebout AW, Smeenk JM, Braat DD, van Leeuwen FE, Verhaak CM. Women's adjustment trajectories during IVF and impact on mental health 11-17 years later. Hum Reprod. 2016;31(8):1788. Spaan M, van den Belt-Dusebout AW, Burger CW, , Schats R, Lambalk CB, Kortman M, Laven JSE, Jansen CAM, van der Westerlaken LAJ, Cohlen BJ, Braat DDM, Smeenk JMJ, Land JA, van der Veen F, Evers JLH, van Rumste MME, van Leeuwen FE. Risk of Colorectal Cancer After Ovarian Stimulation for In Vitro Fertilization. Clin Gastroenterol Hepatol. 2016;14(5):729. Van den Belt-Dusebout AW, Burger CW, van Leeuwen FE. Breast cancer risk after ovarian stimulation for in Vitro Fertilization – Reply. JAMA 2016:316(16)1713. Spaan M, van den Belt-Dusebout AW, Schaapveld M, Mooij TM, Burger CW, van Leeuwen FE. Melanoma risk after ovarian stimulation for in vitro fertilization. Hum Reprod 2015;30:1216-1228. Gameiro S, van der Belt-Dusebout AW, Bleiker E, Braat DDM, van Leeuwen FE, Verhaak CM. Do children make you happier? Sustained child-wish and mental health in women 11-17 years after fertility treatment. Hum Reprod 2014; 29(10):2238-46 Krul IM, Groeneveld E, Spaan M, van den Belt-Dusebout AW, Mooij TM, Hauptmann M, Twisk JWR, Lambers MJ, Hompes PGA, Burger CW, Lambalk CB, van Leeuwen FE. Increased breast cancer risk in in vitro fertilisation treated women with a multiple pregnancy: A new hypothesis based on historical in vitro fertilisation treatment data. Eur J Cancer 2015;51(1):112-20 Buis CC, van Leeuwen FE, Mooij TM, Burger CW; OMEGA Project Group. Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis. Hum Reprod. 2013;28(12)3358-69 Groeneveld E, Lambers MJ, Stakelbeek ME, van den Belt-Dusebout AW, Mooij TM, Heymans MW, Schats R, Hompes PG., Hoek A, Burger CW, van Leeuwen FE and. Lambalk CB on behalf of the OMEGA-project group. Factors associated with dizygotic twinning after IVF treatment with double embryo transfer. Human Rep 2012 Oct; 27(10):2966-70 van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, Laven JS, Jansen CA, Helmerhorst FM, Cohlen BJ, Willemsen WN, Smeenk JM, Simons AH, van der Veen F, Evers JL, van Dop PA, Macklon NS, Burger CW. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 2011; 26(12):3456-3465 Wagenaar K, van Weissenbruch M, van Leeuwen F, Cohen-Kettenis P, Delemarre-van de Waal H, Schats R, Huisman J. Self-reported behavioral and socioemotional functioning of 11- to 18-year-old adolescents conceived by in vitro fertilization.

Fertil Steril. 2011 Feb; 95(2):611-6. Braat DDM, Schutte JM, Bernardus RE, Mooij TM, van Leeuwen FE. Maternal death related to IVF in the Netherlands 1984 – 2008. Hum Reprod May 19 2010; 25(7):1782-86 Haadsma ML, Mooij TM, Groen H, Burger CW, Lambalk CB, Broekmans FJM, van Leeuwen FE, Bouman K, Hoek A, OMEGA Project Group. A reduced size of the ovarian follicle pool is associated with an increased risk of a trisomic pregnancy in IVF treated women. Human Reprod 2010: 25(2):552-8. Ceelen M, Van Weissenbruch MM, Prein J, Smit JJ, Vermeiden JP, Spreeuwenberg M, van Leeuwen FE, Delemarre-van de Waal HA. Growth during infancy and early childhood in relation to blood pressure and body fat measures at age 8 – 18 years of IVF children and spontaneousely conceived controls born in subfertile parents. Human Reprod 2009: 24(11);2788-95. Marees T, Dommering CJ, Imhof SM, Kors WA, Ringens PJ, Van Leeuwen FE, Moll AC. Incidence of retinoblastoma in Dutch children conceived by IVF: an expanded study. Human Reprod 2009; 24(12):3220-24 te Velde ER, Merkus JM, van Leeuwen FE, Verloove-Vanhorick SP, Braat DD. [Sensible family planning: pitfalls and dilemmas]. Ned Tijdschr Geneeskd 2008; 152(48):2592-2595 Ceelen M. Van Weisssenbruch MM, Vermeuden JP, van Leeuwen FE, Delemarre-van de Waal HA. Pubertal development in children and adolescents born after IVF and spontaeous conception. Human Reprod 2008; 23(12):2791-8. Ceelen M, van Weissenbruch MM, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Growth and development of childeren born after in vitro fertilization. Fertil Steril 2008; 90(5):1662-73. Ceelen M, van Weissenbruch MM, Vermeiden JPW, van Leeuwen FE, Delemarre-van de Waal HA. Cardiometabolic differences in children born after in vitro fertilization. J Clin Endocrinol Metab 2008: 93:1682-1688. Ceelen M, van Weissenbruch MM, Roos JC, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Body composition in children and adolescents born after in vitro fertilization or spontaneous conception. J Clin Endocrinol Metab 2007; 92:3417-3423. Kapiteijn K, de Bruijn CS, de Boer E, de Craen AJ, Burger CW, van Leeuwen FE, Helmerhorst FM: Does subfertility explain the risk of poor perinatal outcome after IVF and ovarian hyperstimulation?. Hum Reprod 2006; 21:3228-3234. Van der Gaast MH, Eijkemans MJC, van der Net JB, de Boer EJ, Burger CW, van Leeuwen FE, Fauser BCJM, Macklon NS. The optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online 2006; 13(4):476-480. De Boer EJ, Tonkelaar ID, Burger CW, van Leeuwen FE; on behalf of the OMEGA-project group. Are cause of subfertility and in vitro fertilization treatment risk factors for an earlier start of menopause? Menopause 2005; 12(5):578-588. Lintsen AM, Pasker-de Jong PC, de Boer EJ, Burger CW, Jansen CA, Braat DD, van Leeuwen FE. on behalf of the OMEGA project group. Effects of subfertility cause, smoking and body weight on the success rate of IVF. Hum Reprod. 2005; 20(7):1867-75. de Boer EJ, van Leeuwen FE, den Tonkelaar I, Jansen CA, Braat DD, Burger CW. [Methods and results of in-vitro fertilisation in the Netherlands in the years 1983-1994]. Ned Tijdschr Geneeskd 2004; 148(29):1448-1455

De Boer EJ, den Tonkelaar I, Burger CW, Looman CWN, van Leeuwen FE, te Velde ER, on behalf of the OMEGA project group. The number of retrieved oocytes does not decrease during consecutive gonadotrophin-stimulated IVF cycles. Hum Reprod 2004; 19(4):899-904. Sadrzadeh S, Klip, WAJ, Broekmans FJM, Schats R, Willemsen WNP, Burger CW, van Leeuwen FE, Lambalk CB, for the OMEGA Project group. Birth weight and age at menarche in patients with polycystic ovary syndrome or diminished ovarian reserve, in a retrospective cohort. Human Reproduction 2003; 18(10):2225-2230. De Boer EJ, den Tonkelaar I, te Velde ER, Burger CW, van Leeuwen FE, on behalf of the OMEGA-project group. Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. Hum Reprod 2003; 18(7):1544-1552. Klip H, Van Leeuwen FE, Schats R, Burger CW, For The OMEGA Project Group. Risk of benign gynaecological diseases and hormonal disorders according to responsiveness to ovarian stimulation in IVF: a follow-up study of 8714 women. H um Reprod. 2003;18(9):1951-1958. Moll AC, Imhof SM, Cruysberg JRM, Schouten-van Meeteren AYN, Boers M, Van Leeuwen FE. Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet 2003; 361(9354):309-310. Moll AC, Imhof SM, Schouten-van Meeteren AY, Van Leeuwen FE. In-vitro fertilisation and retinoblastoma. Lancet 2003; 361(9366):1392.[letter]. De Boer, E. J., den Tonkelaar, I., te Velde, E. R., Burger, C. W., Klip, H., Van Leeuwen, F. E. A Low Number of Retrieved Oocytes at in vitro Fertilization Treatment Is Predictive of Early Menopause. Fertil.Steril. 2002; 77(5):978-85. Klip H, Verloop J, Van Gool JD, Koster META, Burger CW, Van Leeuwen FE, for the OMEGA project group. Hypospadias in sons of women exposed to Diethylstilboestrol in utero: a cohort study. Lancet 2002: 359: 1102-1107. Klip WHA, Burger CW, de Kraker J, Van Leeuwen FE. Risk of cancer in the offspring of women who underwent ovarian stimulation for IVF. Human Reprod 2001; 16(11):2451-2458. Klip H, Burger CW, Kenemans P, Van Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control 2000; 11:319-344.

IV General cancer epidemiology and mixed topics

De Boer M, Van Leeuwen FE, Hauptmann M, Overbeek LIH, De Boer JP, Hijmering NJ, Sernee A, Klazen CAH, Lobbes MBI, Van der Hulst RRW, Rakhorst HA, De Jong D. Breast implants and the risk of anaplastic large cell lymphoma in the breast. JAMA oncology. 2018; 4(3):335-341. doi: 10.1001/jamaoncol.2017.4510. de Boer M, van der Sluis WB, de Boer JP, Overbeek LIH, van Leeuwen FE, Rakhorst HA, van der Hulst R, Hijmering NJ, Bouman MB, de Jong D. Breast Implant-Associated Anaplastic Large-Cell Lymphoma in a Transgender Woman. Aesthetic surgery journal. 2017;37(8):Np83 Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, Romieu I, Segnan N, Wardle J, Wiseman M, Belardelli F, Bettcher D, Cavalli F, Galea G, Lenoir G, Martin-Moreno JM, Nicula FA, Olsenm J H, Patnick J, Primic-Zakelj M, Puska P, van Leeuwen FE, Wiestler O, W. Z, Working Groups of Scientific Experts. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epid. 2015;39:S1. Bogers RP, Van Leeuwen FE, Grievink L, Schouten LJ, Kiemeney LALM, Schram-Bijkerk D. Cancer incidence in Dutch Balkan Veterans. Cancer Epid 2013 37(5):550-5 Brandsma M, Baas F, de Bakke PI, Beem EP, Boomsma DI, Bovenberg J, Bueno-de-Mesquita B, van Duijn C, Kiemeney LA, Klungel O, de Leeuw PW, van Leeuwen FE, Ridder-Numan J, Stolk RP, Slagboom PE, SwertzM , Wijmenga C, van Ommen GJB. How to kickstart a national biobanking infrastructure – experiences and prospects of BBMRI-NL. Norsk Epidemiologi 2012; 21(2): 143-148.

EliasS,GrootersHG,Bausch‐GoldbohmRA,vandenBrandtPA,KampmanE,vanLeeuwenFE,PeetersPH,deVriesE,WiggerS,KiemeneyLA. [TheDutchCancerSocietyCancerRiskTest].[ArticleinDutch]NedTijdschrGeneeskd.2012;156(21):A4888. van Rhoon G, Aleman A, Kelfkens G, Kromhout H, van Leeuwen F, Savelkoul H, Wadman W, Van De Weerdt R, Zwamborn AP, van Rongen E, The Electromagnetic Fields Committee of The Health Council of The Netherlands. Health Council of the Netherlands: No need to change from SAR to time-temperature relation in electromagnetic fields exposure limits. Int J Hyperthermia 2011; 27(4):399-404 Schouten LJ, Steevens J, Huysentruyt CJ, Coffeng CE, Keulemans YC, van Leeuwen FE, Driessen AL, van den Brandt PA. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2011; 9(9):754-761 van Rhoon G, Aleman A, Kelfkens G, Kromhout H, van Leeuwen FE, Savelkoul H, Wadman W, Van De Weerdt R, Zwamborn AP, van Rongen E, The Electromagnetic Fields Committee of The Health Council of The Netherlands. Health Council of the Netherlands: No need to change from SAR to time-temperature relation in electromagnetic fields exposure limits. Int J Hyperthermia 2011; 27(4):399-404 Visser O, van Leeuwen FE. Cancer risk in first generation migrants in North-Holland/Flevoland, The Netherlands, 1995-2004. Eur J Cancer 2007; 42:901-908. Visser O, van Leeuwen FE. Stage-specific survival of epithelial cancers in North-Holland/ Flevoland, The Netherlands. Eur J Cancer 2005; 41(15):2321-30 Visser O, van Wijnen JH, van Leeuwen FE. Incidence of cancer in the area around Amsterdam Airport Schiphol in 1988-2003: a population-based ecological study. BMC Public Health 2005; 5:127.

Visser O, van Peppen AM, Ory FG, van Leeuwen FE. Results of breast cancer screening in first generation migrants in Northwest Netherlands. Eur J Cancer Prev. 2005; 14(3):251-5. Van Barneveld TA, Sasco AJ, van Leeuwen FE. A cohort study of cancer mortality among Biology Research Laboratory workers in The Netherlands. Cancer Causes Control 2004; 15:55-66. Van Rongen E, Roubos EW, van Aernsbergen LM, Brussaard G, Havenaar J, Koops FB, van Leeuwen FE, Leonhard HK, van Rhoon GC, Swaen GMH, van de Weerdt RHJ, Zwamborn APM. Mobile Phones and Children: Is Precaution Warranted? Bioelectromagnetics 2004; 25(2):142-144. van Leeuwen FE. [Passive smoking: an environmental health risk]. Ned Tijdschr Geneeskd 2004; 148(29):1465-1466 Visser O, van Wijnen JH, van Leeuwen FE. Residential traffic density and cancer incidence in Amsterdam, 1989-1997. Cancer Causes and Control 2004; 15:331-339. Visser O, Busquet EH, van Leeuwen FE, Aaronson NK, Ory FG. [Incidence of cervical cancer in women in North-Holland by country of birth from 1988-1998]. Ned Tijdschr Geneeskd 2003; 147(2):70-74. Treffers PE, Hanselaar AG, Helmerhorst TJ, Koster ME, van Leeuwen FE. [Consequences of diethylstilbestrol during pregnancy; 50 years later still a significant problem]. Ned Tijdschr Geneeskd 2001; 145(14): 675-680. Jaspers, M. W. M., Caron, H., Heinen, R., Behrendt, H., van Leeuwen, F. The development of a new information model for a pediatric cancer registry on late treatment sequelae in the Netherlands. Proc Medical Informatics Europe, 2000, 'Medical Infobahn Europe', 895-900. Van Leer EM, Coebergh JW, van Leeuwen FE. [Trends in cancer incidence and cancer mortality in the Netherlands: good and bad news]. Ned Tijdschr Geneeskd 1999; 143(9): 1502-1506. Vander Poorten VLM, Balm AJM, Hilgers FJM, Tan IB, Loftus-Coll BM, Keus RB, van Leeuwen FE, Hart AAM. The development of prognostic score for patients with parotid carcinoma. Cancer 1999;85: 2057-2067. Visser O, van Wijnen JH, Benraadt J, van Leeuwen FE. [Cancer incidence in the Schiphol area in 1988 – 1993). Ned Tijdschr Geneeskd 1997; 141 (10): 468-473 Van Barneveld TA, Borst P, van Leeuwen FE. [Passive smoking and lung cancer: a neuw report in perspective]. Ned Tijdschr Geneeskd 1997;141(3):132-136. Van der Sanden GAC, Coebergh JWW, Schouten LJ, Visser O, van Leeuwen FE. Cancer incidence in the Netherlands in 1989 and 1990: first results of the nationwide Netherlands Cancer Registry. Eur J Cancer 1995; 31A: 1822-1829. Van Leeuwen FE. The risk of lung cancer in nonsmokers in the United States: a causal association with environmental tobacco smoke. J Clin Epidemiol 1995; 48: 599-601.

Van Schooten JF, Jongeneelen FJ, Hillebrand MJX, van Leeuwen FE, De Looff JA, Dijkmans APG, Van Rooij JGM, Den Engelse L, Kriek E. Polycyclic aromatic hydrocarbon-DNA adducts in white blood cell DNA and 1-hydroxypyrene in the urine from aluminum workers: relation with job category and synergistic effect of smoking. Cancer Epidemiol Biomarkers and Prevention 1995; 4: 69-77. Van Barneveld TA, Jansen dF, van Leeuwen FE. [The relationship between passive smoning and lung cancer]. Ned tijdschr Geneeskd 1994; 138(10:500-503. Jansen DF, Van Barneveld TA, van Leeuwen FE. Passive smoking and lung cancer: The EPA report. Smoking Prevention: Newsletter European Bureau for Action on Smoking Prevention 1993; 5 (22): 4-6. Kriek E, Van Schooten FJ, Hillebrand MJX, van Leeuwen FE, Den Engelse L, De Looff AJA, Dijkmans APG. DNA adducts as a measure of lung cancer risk in humans exposed to polycyclic aromatic hydrocarbons. Environ Health Perspect 1993; 99: 71-75. Van Schooten FJ, Hillebrand MJX, van Leeuwen FE, Van Zandwijk N, Jansen HM, Den Engelse L, Kriek E. Polycyclic aromatic hydrocarbon - DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels in lung. Carcinogenesis 1992; 13(6): 987-993. Bergman E, Kluck HM, van Leeuwen FE, Crommelin MA, Dekker G, Hart AAM, Coebergh JWW. The influence of age on treatment choice and survival of elderly breast cancer patients in southeastern Netherlands. A population-based study. Eur J Cancer 1992; 28A: 1475-1480. Bergman E, Dekker G, Van Leeuwen FE, Huisman SJ, Van Dam FSAM, Van Dongen JA. The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer 1991; 67: 2227-34. Bergman E, Dekker G, Van Kerckhoff EHM, Peterse HL, Van Dongen JA, van Leeuwen FE. The influence of age and comorbidity on treatment choice and its effect on survival in elderly patients with breast cancer. Breast Cancer Res Treat 1991; 18: 189-98. Van Schooten FJ, Hillebrand MJX, van Leeuwen FE, Lutgerink JT, Van Zandwijk N, Jansen HM, Kriek E. Polycyclic aromatic hydrocarbon-DNA adducts in lung tissue from lung cancer patients. Carcinogenesis 1990; 1:1677-1681. Van Schooten FJ, van Leeuwen FE, Hillebrand MJX, De Rijke ME, Hart AAM, Van Veen HG, Oosterink S, Kriek E. Determination of benzo[a]pyrene diol epoxide-DNA adducts in lymphochyte DNA from coke oven workers with polyclonal antibodies. The impact of smoking. J Natl Cancer Inst 1990; 82:927-933. Jongeneelen FJ, van Leeuwen FE, Oosterink S, Anzion RBM, Van der Loop F, Bos RP, Van Veen HG. Ambient and biological monitoring of coke oven workers: determinants of the internal dose of polycyclic aromatic hydrocarbons. Br J Ind Med 1990; 47:454-461 Van Leeuwen FE, Van Schooten FJ, Kriek E. Epidemiologic studies of passive smoking and lung cancer - a possible role for benzo[a]pyrene-DNA adduct measurements. Toxicol Environ Chem 1988; 16: 309-324 Van Schooten FJ, Kriek E, Steenwinkel MJST, Noteborn HPJM, Hillebrand MJX, van Leeuwen FE. The binding efficiency of polyclonal and monoclonal antibodies to DNA modified with benzo[a]pyrene diolepoxide is dependent on the level of modification. Implications for quantification of benzo[a]pyrene-DNA adducts in vivo.

Carcinogenesis 1987; 8:1263-1269. De Vet HCW, van Leeuwen FE. Dietary guidelines for cancer prevention: the etiology of a confused debate. Nutr Cancer 1986; 8, 223-229. De Vet HCW, van Leeuwen FE. On the reliability of historical dietary information [letter, reply]. Am J Epidemiol 1986; 123:555-556. Van Leeuwen FE, De Vet HCW, Hayes RB, Van Staveren WA, West CE, Hautvast JGAJ. An assessment of the relative validity of retrospective interviewing for measuring dietary intake. Am J Epidemiol 1983; 118, 752-758. Van der Hoeven JCM, Van Leeuwen FE. Isolation of a mutagenic fraction from bracken (Pteridium aquilinum). Mutation Res 1980; 79: 377-380.

V Methods, privacy legislation and ethical issues Vermeulen E, Rebers S, Aaronson NK, Brandenburg AP, van Leeuwen FE, Schmidt MK. Patients’ Attitudes Towards the Return of Incidental Findings After Research with Residual Tissue: A Mixed Methods Study. GENETIC TESTING AND MOLECULAR BIOMARKERS 2018; DOI: 10.1089/gtmb.2017.0222 Kilsdonk E, Wendel E, van Dulmen-den Broeder E, van Leeuwen FE, van den Berg MH, Jaspers MW. Participation rates of childhood cancer survivors to self-administered questionnaires: a systematic review. European journal of cancer care. 2017;26(6). Rebers S, Aaronson NK, van Leeuwen FE, Schmidt MK. Exceptions to the rule of informed consent for research with an intervention. BMC Medical Ethics. 2016;17(1):1. Rebers S, Vermeulen E, Brandenburg AP, Stoof TJ, Zupan-Kajcovski B, Bos WJ, Jonker MJ, Bax CJ, van Driel WJ, Verwaal VJ, van den Brekel MW, Grutters JC, Tupker RA, Plusjé L, de Bree R, Schagen van Leeuwen JH, Vermeulen EG, de Leeuw RA, Brohet RM, Aaronson NK, Van Leeuwen FE, Schmidt MK. A Randomised Controlled Trial of Consent Procedures for the Use of Residual Tissues for Medical Research: Preferences of and Implications for Patients, Research and Clinical Practice. PloS one. 2016;11(3):e0152509. Lanting CI, de Vroome EMM, Elias JG, van den Brandt PA, van Leeuwen FE, Kampman E, Kiemeney LA, Peeters PHM, de Vries E, Basch-Goldbohm RA. [Congriburion of life style factors to cancer risk] Ned Tijdschr Geneeskd 2014;15B:A8085 (Article in Dutch) OverbeekA,vandenBergMH,HukkelhovenCW,KremerLC,vandenHeuvel‐EibrinkMM,TissingWJ,LoonenJJ,VersluysAB,BrestersD,KaspersGJ,LambalkCB,vanLeeuwenFE,vanDulmen‐denBroederE;DCOGLATER/VEVOStudyGroup. Validityofself‐reporteddataonpregnanciesforchildhoodcancersurvivors:acomparisonwithdatafromanationwidepopulation‐basedregistry.HumanRep2013Mar;28(3):819‐27 Rebers S, Van der Valk T, Meijer GA, van Leeuwen FE, Schmidt MK. [The future of consent for the secondary use of human tissue: in the patient’s interest?] Ned. Tijdschr. Geneesk. 2012; 156(21):A4485. Pijpe A, Mulder RL, Manders P, van Leeuwen FE, Rookus MA. Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers. J Clin Epidemiol 2011 Dec; 64(12):1434-43. Schmidt MK, Vermeulen E, Tollenaar RA, van ’t Veer LJ, van Leeuwen FE. Regulatory aspects of genetic research with residual human tissue: Effective and efficiënt data coding. Eur J Cancer. 2009 Sep; 45(13):2376-82. Van den Berg MH, Overbeek A, van der Pal HJ, Versluys AB, Bresters D, van Leeuwen FE, Lambalk CB, Kaspers GJ, Dulmen-den Broeder E.

Using web-based and paper-based questionnaires for collecting data on fertility issues among female childhood cancer survivors: differences in response characteristics. J Med Internet Res 2011; 13(3):e76 Vermeulen E, Schmidt MK, Cornel MC, Knoppers BM, van Leeuwen FE, Aaronson NK, Connective tissue: Cancer patients’ attitudes towards medical research using excised (tumour) tissue. BioSocieties nov 2011; 6(4):466-486 . Pijpe A, Manders P, Mulder RL, van Leeuwen FE, Rookus MA. Reliability of self-reported diagnostic radiation history in in BRCA1/2 mutation carriers. Eur J Epidemiol 2010; 25(2):103-113 Van den Berg MH, Dulmen-den Broeder E, Overbeek A, Twisk JWR, Schats R, van Leeuwen FE, Kaspers GJ, Lambalk CB. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Hum Reprod 2010; 25(6):1520-1527 Vermeulen E, Schmidt MK, Aaronson NK, Kuenen M, van der Valk P, Sietses C, van den Tol P, van Leeuwen FE. Opt-out plus, the patients’ choice: preferences of cancer patients concerning information and consent regimen for future research with biological samples archived in the context of treatment J. Clin Path 2009; 62(3):275-8. Vermeulen E, Schmidt MK, Aaronson NK, Kuenen M, Baas-Vrancken Peters MJ, van der Poel H, Boot H, Verwaal VJ, Cats A, van Leeuwen FE. A trial of consent procedures for future research with clinically-derived biological samples. Br J Cancer 2009; 101:1505-12. Vermeulen E, Geesink I, Schmidt MK, Steegers C, Verhue D, Brom FW, Aaronson NK, van Leeuwen FE. [Secondary use of human tissue: consent and better information required]. Ned Tijdschr Geneeskd 2009; 153:A948 de Kok IM, Habbema JD, Mourits MJ, Coebergh JW, van Leeuwen FE. [Grounds for the inclusion of vaccination against cervical cancer within the National Immunisation Programme]. Ned Tijdschr Geneeskd 2008; 152(48):2639-2640 Vermeulen E, Schmidt MK, Aaronson NK, Kuenen M, van Leeuwen FE. Obtaining 'fresh' consent for genetic research with biological samples archived ten years ago. Eur J Cancer 2009: 45(7):1168-74 De Kok IM, Habbema JD, Mourits MJ, Coebergh JW, van Leeuwen FE. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands]. Ned Tijdschr Geneeskd 2008; 152(37):2001-2004 van Erp EJ, Heintz AP, Helmerhorst TJ, Koster ME, van Leeuwen FE. [Settlement effected for damages for victims of diethylstilbestrol (DES)]. Ned Tijdschr Geneeskd 2007; 151(21):1197-1200 Van Leeuwen FE, van Erp EJ, Helmerhorst TJ, Heintz PA. Compensation for diethylstilbestrol injury. Lancet 2007; 369(9569):1258. Hoogendoorn WE, Casparie MK, van Leeuwen FE. [Rapid tracing of new patients with cancer through the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA) in order to freeze tumour material for molecular-epidemiological research]. Ned Tijdschr Geneeskd 2005; 149(40):2222-2227 De Boer EJ, den Tonkelaar I, Burger CW, van Leeuwen FE, for the OMEGA-project group.

Validity of self-reported causes of subfertility. Am J Epidemiol. 2005; 161(10):978-86. Ronckers C, Land C, Hayes R, Verduijn P, van Leeuwen F. Factors impacting questionnaire response in a Dutch retrospective cohort study. Ann Epidemiol 2004; 14(1):66-72. Klaren HM, van't Veer LJ, van Leeuwen FE, Rookus MA. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 2003; 95(13):941-947. Van Leeuwen FE, Schornagel JH [Save or destroy? The importance of medical record for former patients and future patients]. Ned Tijdschr Geneeskd 2001; 145(10):455-460. Schmidt MK, van Leeuwen FE, Klaren HM, Tollenaar RA, van ’t Veer Lj. [Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy]. Ned Tijdschr Geneeskd 2004; 83(1): 91-93.

Book chapters (English) Van Leeuwen FE, De Vet HCW. Dietary recommendations in cancer prevention: does the end justify the means? In: Joossens JV, Hill MJ, Geboers J (eds). Diet and human carcinogenesis. Proc. 3rd Ann.Symp. ECP, Aarhus, Denmark, June 1985, p329-334. Exc Med Int Congress Series no 685. Excerpta Medica, Elsevier Science Publishers BV, Amsterdam. Van Leeuwen FE, Coebergh JWW. Descriptive epidemiology of cancer in the elderly in The Netherlands. In: Ten Bokkel Huinink WW (ed). Cancer in the Elderly: 75th anniversary of The Netherlands Cancer Institute: Proceedings of a symposium, Amsterdam, 3 June 1988, Amsterdam: Excerpta Medica. Bergman E, Van Kerkhoff EHM, Huisman SJ, van Leeuwen FE, Van Dam FSAM. Strategies for the treatment of elderly cancer patients, with special emphasis on breast cancer. In: Ten Bokkel Huinink WW (ed). Cancer in the elderly: 75th anniversary of The Netherlands Cancer Institute: Proceedings of a symposium, Amsterdam, 3 june 1988. Amsterdam: Excerpta Medica. Van Leeuwen FE, Van Dongen JA. Breast cancer. In: De Winter GA, Coebergh JWW, Van Leeuwen FE, Schouten LJ (eds). Incidence of cancer in the Netherlands 1989: First report of the Netherlands Cancer Registry. LOK/Coordinating Centre of Comprehensive Cancer Centers, Utrecht.1992. Van Leeuwen FE. The cancer registry as a tool for research and health care planning. In: De Winter GA, Coebergh JWW, Van Leeuwen FE, Schouten LJ (eds). Incidence of cancer in the Netherlands 1989: First report of the Netherlands Cancer Registry. LOK/Coordinating Centre of Comprehensive Cancer Centers, Utrecht. 1992. Coebergh JWW, Van Leeuwen FE, Wagenaar Sj Sc. Lung cancer. In: De Winter GA, Coebergh JWW, Van Leeuwen FE, Schouten LJ (eds). Incidence of cancer in the Netherlands 1989: First report of the Netherlands Cancer Registry. LOK/Coordinating Centre of Comprehensive Cancer Centers, Utrecht. 1992. Rookus MA, Van Leeuwen FE. A case-control study of oral contraceptives and breast cancer risk. In: De Winter GA, Coebergh JWW, Van Leeuwen FE, Schouten LJ (eds). Incidence of cancer in the Netherlands 1989: First report of the Netherlands Cancer Registry. LOK/Coordinating Centre of Comprehensive Cancer Centers, Utrecht. 1992. Van Leeuwen FE, Benraadt J. Risk of endometrial cancer following breast cancer: a relationship with tamoxifen? In: De Winter GA, Coebergh JWW, Van Leeuwen FE, Schouten LJ (eds). Incidence of cancer in the Netherlands 1989: First report of the Netherlands Cancer Registry. LOK/Coordinating Centre of Comprehensive Cancer Centers, Utrecht. 1992. Van Leeuwen FE, Stiggelbout AM, Van den Belt-Dusebout AW, Noyon R, Eliel MR, Van Kerckhoff EHM, Delemarre, JFM, Somers R. Risk of second cancer following treatment of testicular cancer. Incidence of cancer in the Netherlands 1989: First report of the Netherlands Cancer Registry. LOK/Coordinating Centre of Comprehensive Cancer Centers, Utrecht. 1992. Van Leeuwen FE, Stiggelbout AM, Delemarre JFM, Somers R. Second cancer risk following testicular cancer. In: Jones WG, Harnden P, Appleyard I, editors. Germ cell tumours III. Proceedings of the third germ cell tumour conference; 1993 Sept 8-10; Leeds, UK: Pergamon, 359-369. (Advances in the Biosciences; Vol 91; Elsevier Science Ltd). 1994. Ned Van der Kooy K, Rookus MA, Peterse HL, van Leeuwen FE. P53 and neu (c-erbB-2) overexpression in relation to risk factors for breast cancer. In: Li JJ, Li SA, Gustafsson JA, Nandi S, Sekely LI (eds). Hormonal carcinogenesis II. Proceedings of the second international symposium. New York: Springer-Verlag, 1996; 378-382. Van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. In: Löwenberg B (ed). Baillière Clinical Haematology: international practice and research. Acute myelogenous leukaemia and myelodysplasia (vol 9, no 1). London: Ballière Tindall, 1996: 57-85. Van Leeuwen FE. Second cancers. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: principles and practice of oncology (ed 5). Philadelphia, PA: Lippincott, 1997: 2773-2796.

Van Leeuwen FE, Swerdlow AJ, Valagussa P, Tucker MA. Second cancers after treatment of Hodgkin’s disease. In: Mauch P, Armitage J, Diehl V, Hoppe R, Weiss L, editors. Hodgkin's disease. Philadelphia: Lippincott Williams & Wilkins, 1999: 607-632. van Leeuwen FE. In: Methods of assessing second cancer risk: the example of Hodgkin's disease, in Perry MC (ed) : 2000 Educational Book. For the 36th Annual Meeting of the American Society of Clinical Oncology. Alexandria, VA, American Society of Clinical Oncology, 2000, pp 562-572. Van Leeuwen FE, Travis, LB. Second cancers. DeVita VT Jr, Hellman S, Rosenberg SA (eds.). Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins. 2001;6: 2939-2960. Swerdlow AJ and van Leeuwen FE. Late effects after treatment for Hodgkin lymphoma. In: Degos L, Griffin JD, Linch DC, Löwenberg B, editors. Textbook of Malignant Haematology 2nd ed. London: Martin Dunitz ltd. 2004; 753-768. Van Leeuwen FE and Travis LB. Second Cancers. Pp. 539-548. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL (Eds.). Non-Hodgkin's Lymphoma, Philadelphia: Lippincott Williams & Wilkins, 2004. Van Leeuwen FE, Travis LB. Second cancers. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: principles and practice of oncology (ed 7). Philadelphia, PA: Lippincott, 2005: 2575-2602. Van Leeuwen FE, Swerdlow AJ, Travis LB. Second cancers after treatment of Hodgkin lymphoma. In: Hoppe RT, Mauch PM, Armitage JO, Diehl V, Weiss LM. (Eds.). Hodgkin Lymphoma, second edition. Philadelphia: Lippincott Williams & Wilkins. 2007; 347-370. Travis LB, Hodgson D, Allen J, van Leeuwen FE. Second cancers. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: principles and practice of oncology (ed 8). Philadelphia, PA: Lippincott 2008: (2) 2718-2742. Ng AK, van Leeuwen FE, Mauch PM. Second tumors: In: Armitage JO, Mauch PM, Haris NL, Coiffier B, Dalla-Favera R (eds). Non-Hodgkin Lymphomas (second edition): Lippincott, Williams & Wilkins 2010; 463-471. Hodgson D.C., Van Leeuwen FE. Second malignancy risk after treatment of Hodgkin Lymphoma. In: Engert A., Horning S.J., editors. Hematologic Malignancies: Hodgkin Lymphoma. A comprehensive Update on Diagnostics and Clinics. Berlin Heidelberg: Springer Verlag, 2010: 305-331 Moll A, Bosscha M, Van Leeuwen FE, Marees T. Long-term survivors of retinoblastoma: Risk of increased second malignancy. In: Tumors of the Central Nervous System, volume 8. M.A. Hayat eds. Springer Science + Business Media, Dordrecht, 2012. Hodgson DC, van Leeuwen FE. Second malignancy risk after treatment of Hodkin Lymphoma. In: Engert A, Younes A. (eds) Hodgkin Lymphoma, a comprehensive overview. Second edition . Berlin Heidelberg: Springer Verlag, 2015: 375 – 410. Van Leeuwen FE, Ng A. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program 2016: 323-330 Dutch Journals Van Leeuwen FE, De Vet HCW et al. De relatieve validiteit van retrospectief voedselconsumptie-onderzoek. Tijdschrift voor Sociale Gezondheidszorg 1983; 61:833-835. De Vet HCW, van Leeuwen FE. Methodologische aspecten van epidemiologisch onderzoek naar het verband tussen voeding en kanker. Voeding 1983; 44:298-304. Van Leeuwen FE, De Vet, HCW. Voedingsaanbevelingen in kanker preventie: nu, ooit of nooit. Voeding 1984; 45:361-371.

Berkel J, Van Faassen A, van Leeuwen FE, Sinkeldam EJ. Voeding en coloncarcinoom. Deel 1: Epidemiologie. Voeding 1984; 45:150-158. Berkel J, Van Faassen A, van Leeuwen FE, Sinkeldam EJ. Voeding en coloncarcinoom. Deel 2: Experimentele studies. Voeding 1984; 45:150-158. De Vet HCW, van Leeuwen FE. Diet and human carcinogenesis. Verslag van het derde ECP-symposium, 19-21 juni 1985, Arhus, Denemarken. Voeding 1985; 46:350-353. Van Leeuwen FE, Verbeek ALM, Coebergh JWW. Mammacarcinoom en de pil: het nadeel van de twijfel? Ned Tijdschr Geneeskd 1987; 131: 2012-2016. Van Leeuwen FE. Passief roken: een gevaar voor de gezondheid? Kanker 1987; 11:187-189. Van Duijn CM, Zwijsen RML, van Leeuwen FE, Schouten EG. Een vergelijking van expositiegegevens uit twee informatiebronnen: Gebruik van orale anticonceptie volgens gebruikster en voorschrijver. Tijdschr voor Sociale Gezondheidszorg 1987; 7:193-194. Van Leeuwen FE. Passief roken: een risiko voor de gezondheid? Gamma 38:315-321. Somers R, van Leeuwen FE, Taal BG, Van Heerde P, Coster B, Hart AAM. Tweede tumoren na behandeling van de ziekte van Hodgkin. Ned Tijdschr Geneeskd 1988; 132:1358-1362. Rookus MA, van Leeuwen FE. Etiologie van mammacarcinoom IKZ-integraal 1988; 1:25-27. Benraadt J, van Leeuwen FE. Kankerregistratie en epidemiologie. TMI-Tijdschr Med Inform 1988; 17(3):7-11. Van Leeuwen FE. Mammacarcinoom en de pil: een puzzle met ontbrekende stukjes. Ned Tijdschr Geneeskd 1989; 133:2300-2303. Rookus MA, Van Leeuwen FE. Risicofactoren voor borstkanker in kaart gebracht. Kanker 1990; 14:188-192. Somers R, van Leeuwen FE. Tweede tumoren na behandeling van kanker. Kanker 1990; 14:106-109. Van Leeuwen FE, Van Barneveld TA. Geen toename van het aantal mammacarcinomen bij subcutaan estradiolgebruik. Ned Tijdschr Geneeskd 1991; 135:1145-1146. Haring MH, Rookus MA, van Leeuwen FE. Beschermt het geven van borstvoeding tegen borstkanker? Een epidemiologisch onderzoek. Ned Tijdschr Geneeskd 1992; 136:743-747. Bergman E, van Leeuwen FE, van Dongen JA, Kluck HM, Crommelin MA, Coebergh JWW. Behandeling en overleving van oudere borstkankerpatiënten. Ned Tijdschr Heelkunde 1992; 6:31. Van Barneveld TA, Dalesio OB, van Leeuwen FE.

Een ontmoedigend tabaksontmoedigingsbeleid: Pleidooi voor een integrale aanpak. Medisch Contact 1992; 47:943-946. Werkgroep Jaarrapportage Nederlandse Kankerregistratie. Eerste resultaten van de Nederlandse kankerregistratie. Ned Tijdschr Geneeskd 1992; 136: 2418-2421. Bergman L, Crommelin MA, Kluck HM, Van Dongen JA, Coebergh JWW, van Leeuwen FE. De behandeling van oudere en van jongere postmenopausale patiënten met mammacarcinoom verschilt, hun overleving niet. Ned Tijdschr Geneeskd 1993; 137:2386-2391. Osendarp SJM, Ypma EB, van Leeuwen FE, MA Rookus. Vet en het risico op borstkanker. Voeding 1993; 54 (7/8):16-20. Jansen DF, Van Barneveld TA, van Leeuwen FE. Een causaal verband tussen longkanker en passief roken: het rapport van de Amerikaanse Environmental Protection Agency. Ned Tijdschr Geneeskd 1994; 138:500-503. Van Barneveld TA, Jansen DF, van Leeuwen FE. Het verband tussen passief roken en longkanker [letter, reply]. Ned Tijdschr Geneeskd 1994; 138:883-884. Benraadt J, van Leeuwen FE. Endometriumcarcinoom na mammacarcinoom: een relatie met tamoxifen? Ned Tijdschr Geneeskd 1995; 139:1381-1385. Rookus MA, van Leeuwen FE. Orale anticonceptiva en het risico op mammacarcinoom. Ned Tijdschr Geneeskd 1995; 139:1450-1454. Rookus M, Van Leeuwen FE. Verhoogt `de pil' het risico op borstkanker? DES Nieuws 1995; (36):2-3. Rookus MA, Van Leeuwen FE. Verhoogt pilgebruik het risico op mammacarcinoom? Ned Tijdschr Obstet Gynaecol 1995; 108:106-110. Van Leeuwen FE, Kenemans P. Postmenopauzale hormoonsuppletie en borstkanker. Tijdschr Climacterium Postmenopauze 1995; 9:13-14. Hamerlynck JVTH, van Leeuwen FE. Langdurige postmenopauzale hormoonsubstitutie en borstkankerincidentie: de `Nurses' health study'. Ned Tijdschr Geneeskd 1996; 140:759-761. Rookus MA, van Leeuwen FE. Pilgebruik op jonge leeftijd: risico op borstkanker? Tijdschr Kanker 1996; 20:24-27. Bergman L, Benraadt J, Van Leeuwen FE. Tamoxifen: naar welke kant slaat de balans uit? Tijdschr Kanker 1997; 21:12-16. Burger CW, Koomen I, Peters NAJB, van Leeuwen FE, Kenemans P. Postmenopauzale hormonale suppletietherapie en kanker van de vrouwelijke geslachtsorganen en de mamma. Ned Tijdschr Geneeskd 1997; 141:368-372. Van Barneveld TA, Borst P, van Leeuwen FE. Passief roken en longkanker: een nieuw rapport in perspectief. Ned Tijdschr Geneeskd 1997; 141:132-136. Visser O, Van Wijnen JH, Benraadt J, van Leeuwen FE.

Incidentie van kanker in de omgeving van Schiphol in 1988-1993. Ned Tijdschr Geneeskd 1997; 141:468-473. Bergman L, van Leeuwen FE, Benraadt J. Tamoxifen en het voordeel van de twijfel. Pharmaceutisch Weekblad 1998; 133:170-173. Rookus MA, van Leeuwen FE, Hamerlynck JVTH. Het laatste woord over hormoonsuppletie en borstkanker? Ned Tijdschr Geneeskd 1998; 142:111-3. Van Leeuwen FE. Risico op tweede tumoren na behandeling van de ziekte van Hodgkin. Tijdschr Kanker 1998; 22:38-42. Van Leer EM, Coebergh JW, van Leeuwen FE: Trends in kankerincidentie en sterfte door kanker in Nederland: goed en slecht nieuws Ned Tijdschr Geneeskd 1999; 143:1502-1506 Aleman BMP, Klokman WJ, van Leeuwen FE: [Second primary tumors in patients treated at an early age for Hodgkin's disease; consequences for the follow-up]. Ned Tijdschr Geneeskd 2000; 144:1517-1520. Klip H, van Leeuwen FE, Burger C. Risico op ovariumcarcinoom na gebruik van fertiliteitsbevorderende geneesmiddelen. Tijdschrift voor Fertiliteitsonderzoek 2000; 14:16-21. Van Leeuwen FE, W.J. Klokman, M.B. van ’t Veer, B.M.P. Aleman. Het langetermijn-risico van tweede tumoren na behandeling van de ziekte van Hogdkin tijdens adolescentie of jongvolwassenheid. Ned Tijdschr Geneeskd 2000; 144:2235:2236. Van Leeuwen FE, Schornagel JH: Bewaren of vernietigen? Het belang van het dossier voor de patient van gisteren en morgen. Ned Tijdschr Geneeskd 2001; 145:455-460. Van Leeuwen FE, Ranchor AV, Sanderman R: Epidemiologie van kanker: mate van vóórkomen en risicofactoren, in De Haes JGJM, Gualthérie van Weezel LM, Sanderman R, et al (eds) : Psychologische patiëntenzorg in de oncology. Assen, Koninklijke Van Gorcum BV, 2001, pp 8-26 Treffers PE, Hanselaar AG, Helmerhorst TJ, Koster ME, van Leeuwen FE: Gevolgen van diethylstilbestrol in de zwangerschap: na 50 jaar nog steeds een actueel probleem. Ned Tijdschr Geneeskd 2001; 145:675-680. Van Leeuwen FE, Schornagel JH. Verantwoord omgaan met bewaartermijn medische gegevens [letter, reply]. Ned Tijdschr Geneesk 2001; 45:1090-1091. Visser O, Busquet EH, van Leeuwen FE, Aaronson NK, Ory FG. Incidentie van baarmoederhals-kanker naar geboorteland bij vrouwen in Noord-Holland in 1988-1998. [Incidence of cervical cancer in women in North-Holland by country of birth from 1988-1998]. Ned Tijdschr Geneeskd 2003; 147(2):70-74. Vandenbroucke JP, van Leeuwen FE, Helmerhorst FM: Borstkanker en hormoongebruik rond de menopauze Ned Tijdschr Geneeskd 2003; 147:1829-1834. Vandenbroucke JP, van Leeuwen FE, Helmerhorst FM. Borstkanker en hormoongebruik rond de menopauze. Medisch Contact, 26 december 2003; 52.

Ronckers CM, Verduijn PG, Land CE, Hayes RB, Stovall M, van Leeuwen FE: Geen overtuigend bewijs voor een causaal verband tussen nasofaryngeale radiumbestraling op de kinderleeftijd en latere hoofd-halstumoren en hormonale aandoeningen; een historisch cohortonderzoek. Ned Tijdschr Geneeskd 2004; 148:1775-1780. Schmidt MK, van Leeuwen FE, Klaren HM, Tollenaar RA, 't Veer LJ: Genetisch onderzoek met opgeslagen lichaamsmateriaal: een coderingsprocedure met optimal gebruik van informatie bij behoud van privacy. Ned Tijdschr Geneeskd 2004: 148:564-568 Schmidt MK, van Leeuwen FE, Klaren H, Tollenaar RM, van ‘t Veer LJ. Genetisch onderzoek met opgeslagen lichaamsmateriaal: een coderingsprocedure met optimaal gebruik van informatie bij behoud van privacy [letter, reply]. Ned Tijdschr Geneeskd 2004; 148(25):1264. De Boer EJ, van Leeuwen FE, den Tonkelaar I, Jansen CA, Braat DD, Burger CW: [Methods and results of in-vitro fertilisation in the Netherlands in the years 1983-1994]. Ned Tijdschr Geneeskd 2004; 148:1448-1455. Van Leeuwen FE. Passief roken: een milieurisico. [author reply]. Ned Tijdschr Geneeskd 2004; 148(29);1465-1466. Hoogendoorn WE, Casparie MK, van Leeuwen FE: Snelle signalering door PALGA van nieuwe gevallen van kanker voor een moleculair epidemiologisch onderzoek. Ned Tijdschr Geneeskd 2005; 149:2222-2227. Moll AC, Imhof SM, Schouten-van Meeteren AYN, van Leeuwen FE, Giaccone G. Second primary tumours in hereditary retinoblastoma patients. Ned Tijdschr Oncol 2006; 3:144-151. Postma A, Schouten-van Meeteren AYN, Hakvoort-Cammel FGAL, Bresters D, Versluys AB, Bökkerink JPM, van Dulmen-den Broeder E, van der Pal HJH, van Dam EWCM, van der Linden GHM, Blaauwbroek R, van Leeuwen FE, Jaspers MWM, Kremer LCM, van den Bos C. Gezondheidsproblemen na de behandeling van kinderkanker. Tijdschr Kindergeneeskd 2006; 74(6):209-214. Van Erp EJM, Heintz APM, Helmerhorst ThJM, Koster M.E.Th.A, van Leeuwen FE. Regeling voor schadevergoeding aan slachtoffers van diethylstilbestrol (des) een feit. Ned Tijdschr Geneeskd 2007; 151(21):1197-1200. De Kok IMCM, Habbema JDF, MJE Mourits, Coebergh JWW, Van Leeuwen FE. Onvoldoende gronden voor opname van vaccinatie tegen Humaan papillomavirus in het Rijksvaccinatieprogramma. Ned Tijdschr Geneeskd; 2008;152(37):2001-2006. Sparidans JGM, van Leeuwen FE, De Bruin ML, Aleman BMP. Mammacarcinoom na behandeling voor hodgkinlymfoorm. Ned. Tijdsch Oncolog 2008:5(4);144-149. te Velde ER, Merkus JM, van Leeuwen FE, Verloove-Vanhorick SP, Braat DD. [Sensible family planning: pitfalls and dilemmas] Ned Tijdschr Geneeskd. 2008;152(48):2592-5.

Vermeulen E, Geesink I, Schmidt MK, Steegers C, Verhue D, Brom FWA, Aaronson NK, van Leeuwen FE. Nader gebruik van lichaamsmateriaal: zeggenschap en betere informatie nodig. Ned Tijdschr Geneeskd 2009; 153(52):2524-2529. Elias S, Grooters HG, Bausch-Goldbohm RA, van den Brandt PA, Kampman E, van Leeuwen FE, Peeters PH, de Vries E, Wigger S, Kiemeney LA. [The Dutch Cancer Society Cancer Risk Test].[Article in Dutch] Ned Tijdschr Geneeskd. 2012;156(21):A4888 Lanting CI, de Vroome EMM, Elias JG, van den Brandt PA, van Leeuwen FE, Kampman E, Kiemeney LA, Peeters PHM, de Vries E, Basch-Goldbohm RA. Bijdrage van lijfstijlfactoren aan kanker: secundaire analyse van Nederlandse gegevens voor 2010 met een voorspelling voor 2020 Ned Tijdschr Geneeskd 2014;15B:A8085. Aleman BMP, Van Leeuwen FE. [No evidence for higher risk on coronary damage] Article in Dutch. Ned Tijdschr Geneeskd 2015;159:A8856 Nederlandse boekhoofdstukken en rapporten Somers R, van Leeuwen FE (eds.). Richtlijnen voor het onderzoek en de behandeling van kwaadaardige aandoeningen in het Antoni van Leeuwenhoekhuis; 4e gereviseerde uitgave. Amsterdam, Antoni van Leeuwenhoekhuis.1986. Van Leeuwen FE, De Vet HCW. Methodologische aspecten van het voedselconsumptie-onderzoek. Bijlage 2. In: Rapport Voedingsraad: Factoren in de voeding en het ontstaan van kanker. 1986. Halling AP, Wipkink-Bakker A, van Leeuwen FE. De rol van voeding bij het ontstaan van kanker. In: Informatorium voor Voeding en DiNtetiek (Carbasius-Weber EC, Post GB, Swager TW, eds). Voedingsleer XII 1987; 1-14. Van Leeuwen FE. De rol van voeding bij het ontstaan van kanker: epidemiologische gegevens. In: Nascholingscursus Kanker en Voeding, Nederlandse Vereniging voor DiNtisten 1988: 4-15. Stiggelbout AM, van Leeuwen FE, Dalesio OB. Kanker Signaleringsrapport 1. Stuurgroep Toekomstscenario's Gezondheidszorg. Rijswijk. 1989. Stiggelbout AM, Dalesio OB, van Leeuwen FE. Kanker Signaleringsrapport 2. Rijswijk: Stuurgroep Toekomstscenario's Gezondheidszorg.1990. Van Leeuwen FE, Rookus MA. De rol van orale anticonceptiva bij de epidemiologie van borstkanker. In: Van der Kuy A, Boerrigter PJ (eds). Dertig jaar orale anticonceptie. p49-63. Bussum: Medicom Europe BV.1991. Benraadt J, van Leeuwen FE, Visser O. Jaarverslag kankerregistratie 1989. Amsterdam: IKA, IKA Stedendriehoek Twente.1991. Van Barneveld TA, Dalesio OB, Van Leeuwen FE. Kanker Signaleringsrapport 3. Rijswijk: Stuurgroep Toekomstscenario's Gezondheidszorg. 1992. Visser O, van Leeuwen FE, Benraadt J. Jaarverslag kankerregistratie 1990. Amsterdam: IKA, IKA Stedendriehoek Twente. 1992. Bergman L, Van Zandwijk N, Schaake-koning C, Coebergh JWW, van Leeuwen FE. Longkanker. In: Ruwaard D, Kramers PGN (eds). Volksgezondheid Toekomst Verkenning: De gezondheidstoestand van de Nederlandse bevolking in de periode 1950-2010. Den Haag: Sdu Uitgeverij Plantijnstraat, 1993: 273-279. Van Barneveld TA, van Leeuwen FE. Arbeidsomstandigheden in biologische onderzoekslaboratoria: Het risico op kanker. Den Haag: Ministerie van Sociale Zaken en Werkgelegenheid. 1993. Van Barneveld TA, Horenblas S, Coebergh JWW, van Leeuwen FE. Prostaatkanker. In: Ruwaard D, Kramers PGN (eds). Volksgezondheid Toekomst Verkenning: De gezondheidstoestand van de Nederlandse bevolking in de periode 1950-2010. Den Haag: Sdu Uitgeverij Plantijnstraat, 1993: 288-292.

Van der Sanden GAC, Otter R, Coebergh JWW, van Leeuwen FE. Non-Hodgkin lymfomen. In: Ruwaard D, Kramers PGN (eds). Volksgezondheid Toekomst Verkenning: De gezondheidstoestand van de Nederlandse bevolking in de periode 1950-2010. Den Haag: Sdu Uitgeverij Plantijnstraat, 1993: 293-299. Van der Sanden GAC, Taal BG, Coebergh JWW, van Leeuwen FE. Slokdarmkanker. In: Ruwaard D, Kramers PGN (eds). Volksgezondheid Toekomst Verkenning: De gezondheidstoestand van de Nederlandse bevolking in de periode 1950-2010. Den Haag: Sdu Uitgeverij Plantijnstraat, 1993: 253-258. Voogd AC, Coebergh JWW, Van Dongen JA, van Leeuwen FE. Borstkanker. In: Ruwaard D, Kramers PGN (eds). Volksgezondheid Toekomst Verkenning: De gezondheidstoestand van de Nederlandse bevolking in de periode 1950-2010. Den Haag: Sdu Uitgeverij Plantijnstraat, 1993: 280-287. Visser O, van Leeuwen FE, Benraadt J. Jaarverslag kankerregistratie 1991. Amsterdam: IKA, IKA Stedendriehoek Twente.1993. Van der Sanden GAC, Van Barneveld TA, Dalesio OB, van Leeuwen FE. Kanker, Signaleringsrapport 4, 1994. Rijswijk: Stuurgroep Toekomstscenario's Gezondheidszorg STG. 1994. Visser O, Benraadt J, Sierag JJM, van Leeuwen FE. Feiten en fabels over kanker in Nederland. Amsterdam: Integraal Kankercentrum Amsterdam. 1994. Van Leeuwen FE. Rookus MA. Risicofactoren voor borstkanker. In: Slager E, Buytaert Ph, Devroey P, et al. (eds). Infertiliteit, gynaecologie en obstetrie anno 1997. Proceedings van het congres gehouden op 19, 20 en 21 maart 1997, De Doelen, Rotterdam. Oss: Organon Nederland bv, 1997: 157-162. Visser O, van Leeuwen FE, Benraadt J. Jaarverslag Kankerregistratie 1994. Amsterdam: Integraal Kankercentrum Amsterdam, 1997. Bergman L, Kroon BBR, Coebergh JWW, van Leeuwen FE. Huidkanker. In: Maas IAM, Gijsen R, Lobbezoo IE, Poos MJJC, redactie. Volksgezondheid Toekomst Verkenning 1997. Themarapport 1: De gezondheidstoestand van de bevolking in Nederland: een actualisering. Rijksinstituut voor Volksgezondheid en Milieu. Utrecht: Elsevier/De Tijdstroom 1997: 226-40. Bergman L, Van Zandwijk N, Coebergh JWW, van Leeuwen FE. Longkanker. In: Maas IAM, Gijsen R, Lobbezoo IE, Poos MJJC, redactie. Volksgezondheid Toekomst Verkenning 1997. Themarapport 1: De gezondheidstoestand van de bevolking in Nederland: een actualisering. Rijksinstituut voor Volksgezondheid en Milieu. Utrecht: Elsevier/De Tijdstroom 1997: 217-25. Coebergh JWW, De Jong D, Gerritsen WJ, van Leeuwen FE. Non-Hodgkin lymfomen. In: Maas IAM, Gijsen R, Lobbezoo IE, Poos MJJC, redactie. Volksgezondheid Toekomst Verkenning 1997. Themarapport 1: De gezondheidstoestand van de bevolking in Nederland: een actualisering. Rijksinstituut voor Volksgezondheid en Milieu. Utrecht: Elsevier/De Tijdstroom 1997: 262-8. Van Barneveld TA, Horenblas S, Coebergh JWW, van Leeuwen FE. Prostaatkanker. In: Maas IAM, Gijsen R, Lobbezoo IE, Poos MJJC, redactie. Volksgezondheid Toekomst Verkenning 1997. Themarapport 1: De gezondheidstoestand van de bevolking in Nederland: een actualisering. Rijksinstituut voor Volksgezondheid en Milieu. Utrecht: Elsevier/De Tijdstroom 1997: 253-61. Van Barneveld TA, Taal BG, Coebergh JWW, van Leeuwen FE. Slokdarmkanker. In: Maas IAM, Gijsen R, Lobbezoo IE, Poos MJJC, redactie. Volksgezondheid Toekomst Verkenning 1997. Themarapport 1: De gezondheidstoestand van de bevolking in Nederland: een actualisering. Rijksinstituut voor Volksgezondheid en Milieu. Utrecht: Elsevier/De Tijdstroom 1997: 191-7. Voogd AC, Rutgers EJT, Coebergh JWW, Van Leeuwen FE. Borstkanker. In: Maas IAM, Gijsen R, Lobbezoo IE, Poos MJJC, redactie. Volksgezondheid Toekomst Verkenning 1997. Themarapport 1: De gezondheidstoestand van de bevolking in Nederland: een actualisering. Rijksinstituut voor Volksgezondheid en Milieu. Utrecht: Elsevier/De Tijdstroom 1997: 241-252. Van Leeuwen FE. Het kankerprobleem in cijfers. In: Boerrigter GH, Honing C, Van Leer EM, Van de Poll KW, redactie. De balans van een halve eeuw kankerbestrijding. Houten/Diegem: Bohn Stafleu Van Loghum, 1999: 23-46.

Van Leeuwen FE. Epidemiologie van kanker, inzichten en vooruitzichten. Rede uitgesproken bij de aanvaarding van het ambt van hoogleraar epidemiologie van kanker aan de faculteit der geneeskunde van de Vrije Universiteit te Amsterdam op 18 juni 1999. Van Leer EM, Cleton FJ, van Leeuwen FE (eindredactie). Signaleringsrapport Kanker 1999. Nederlandse Kankerbestrijding.1999. Van Leeuwen FE, Ranchor AV, Sanderman R. Epidemiologie van kanker: mate van vóórkomen en risicofactoren. In: De Haes JGJM, Gualthérie van Weezel LM, Sanderman R, Van der Wiel HBM, redactie. Psychologische patiëntenzorg in de oncologie. Assen: Koninklijke van Gorcum 2001: 8-26. Coebergh JW, Vandenbroucke JP, van Leeuwen FE. Prognose en screening van kanker. In: Van de Velde CJH, Bosman FT, Wagener DJ, redactie. Oncologie, zesde, herziene druk. Houten/Diegem: Bohn Stafleu Van Loghum 2001: 77-108. Schornagel JH, van Leeuwen FE, Rutgers EJTh. Farmacotherapie bij borstkanker: huidige situatie en toekomstverwachtingen. In: Timmerman H, Van den Berg Jeths A, eindredactie. Geneesmiddelen nu en in de toekomst 2002. Volksgezondheid Toekomst Verkenning RIVM. Houten: Bohn Stafleu Van Loghum 2001: 30-52. Coebergh JW, van Leeuwen FE, Vandenbroucke JP. Oorzaken en frequentie van kanker. In: Van de Velde CJH, Bosman FT, Wagener DJ, redactie. Oncologie, zesde, herziene druk. Houten/Diegem: Bohn Stafleu Van Loghum 2001: 35-75. Signaleringscommissie Kanker van KWF Kankerbestrijding. De rol van voeding bij het ontstaan van kanker. Amsterdam: KWF Kankerbestrijding, 2004. van Leeuwen FE, voorzitter van de Werkgroep Voeding en Kanker. Coebergh JW, van Leeuwen FE, Vandenbroucke JP. Oorzaken en frequentie van kanker. In: Van de Velde CJH, van Krieken JHJM, de Mulder PHM, Vermorken JB, redactie. Oncologie, zevende, herziene druk. Houten: Bohn Stafleu Van Loghum 2005: 27-51. Coebergh JW, Vandenbroucke JP, van Leeuwen FE. Prognose en screening van kanker. In: Van de Velde CJH, van Krieken JHJM, de Mulder PHM, Vermorken JB, redactie. Oncologie, zevende, herziene druk. Houten: Bohn Stafleu Van Loghum 2005: 53-71. Signaleringscommissie Kanker van KWF Kankerbestrijding (van Leeuwen FE, voorzitter SCK-werkgroep 'Voeding en Kanker': De rol van voeding bij het ontstaan van kanker. KWF Kankerbestrijding, 2005. Signaleringscommissie Kanker van KWF Kankerbestrijding (van Leeuwen FE, voorzitter SCK-werkgroep 'Bewegen en Kanker': De rol van lichaamsbeweging bij preventie van kanker. KWF Kankerbestrijding, 2005. Van der Pal HH, van Leeuwen FE, Schouten-van Meeteren AYN. Tweede tumoren na behandeling voor jeugdkanker. In: van den Bosch WJHM, Dieleman P, Wiersma Tj, van Weert HCPM, van Rijswijk HCAM, Meyboom-de Jong B, editors. In: Late iatrogene effecten. Bijblijven. Cumulatief Geneeskundig Nascholingssysteem. Bohn Stafleu van Loghum. Houten. Jaargang 22, nummer 8, 2006. Rookus MA, Mooij TM, van Leeuwen FE. Risicofactoren van mammacarcinoom. [Article in Dutch]. In: Wobbes Th, Nortier HWR, Koning CCE (red). Handboek mammacarcinoom. De Tijdstroom. Utrecht. 2007: 29-41. Van Leeuwen FE, Visser O. Epidemiologie van kanker, mate van vóórkomen en risicofactoren (Chapter in Dutch) De Haas H, Gualthérie van Weezel L, Sanderman R (red). IN: Psychologische patiëntenzorg in de oncologie. Handboek voor de professional. Van Gorcum Assen 2009

Zijlstra J.M., Van Leeuwen FE. Late effecten van therapie bij hematologische ziekten. Hoofdstuk 42 In: Leerboek Hematologie. Bob Löwenberg, Gert Ossenkoppele, Nicole Blijlevens, Frank Leebeek, Sonja Zweegman (red.) De Tijdstroom 2015: 735-742.